Form 8-K

8-K — Annovis Bio, Inc.

Accession: 0001104659-26-064514

Filed: 2026-05-20

Period: 2026-05-20

CIK: 0001477845

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2615162d1_8k.htm (Primary)

EX-4.1 — EXHIBIT 4.1 (tm2615162d1_ex4-1.htm)

EX-5.1 — EXHIBIT 5.1 (tm2615162d1_ex5-1.htm)

EX-10.1 — EXHIBIT 10.1 (tm2615162d1_ex10-1.htm)

EX-99.1 — EXHIBIT 99.1 (tm2615162d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2615162d1_ex99-2.htm)

GRAPHIC (tm2615162d1_ex5-1img001.jpg)

GRAPHIC (tm2615162d1_ex5-1img002.jpg)

GRAPHIC (tm2615162d1_ex99-1img001.jpg)

GRAPHIC (tm2615162d1_ex99-2img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2615162d1_8k.htm · Sequence: 1

false

0001477845

2026-05-20

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date

of earliest event reported): May 20, 2026

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-39202

26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

101

Lindenwood Drive, Suite 225

Malvern, PA

19355

(Address of Principal Executive Offices, and

Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including

Area Code

Not

Applicable

(Former Name or Former Address, if Changed Since

Last Report)

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name

of each exchange on which

registered

Common Stock, par value $0.0001 per share

ANVS

New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company,

indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised

financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01

Entry into a Material Definitive Agreement.

On May 20, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”),

dated as of May 20, 2026, with Canaccord Genuity LLC, as underwriter (the “Underwriter”), pursuant to which the Company agreed

to issue and sell, in a public offering (the “Offering”) (i) an aggregate of 7,895,000 shares of common stock (the “Shares”),

$0.0001 par value per share (the “Common Stock”), of the Company and (ii) accompanying common stock warrants to purchase up

to an aggregate of 7,105,500 shares of Common Stock (the “Warrants” and the shares of Common Stock issuable upon exercise

of the Warrants, the “Warrant Shares”). The Warrants are immediately exercisable, expire six years from the date of issuance

and have an exercise price equal to $2.25 per share of Common Stock. The combined offering price of each Share and accompanying nine-tenths

of a Warrant is $1.90 per share. The gross proceeds to the Company from the Offering are expected to be approximately $15 million, before

deducting offering expenses payable by the Company.

The Offering is expected to close on or about

May 21, 2026, subject to the satisfaction of customary closing conditions. The Company currently plans to use the net proceeds from the

Offering, for the continued clinical development of the Company’s lead compound Buntanetap in clinical studies for for Alzheimer’s

disease and Parkinson’s disease, and for working capital and general corporate purposes.

The Underwriting Agreement contains customary

representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company,

including for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of

the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made

only for the purposes of such agreement and as of the specific dates, were solely for the benefit of the parties to such agreement and

may be subject to limitations agreed upon by the contracting parties.

The Offering was made pursuant to the Company’s

effective shelf registration statement on Form S-3 (File No. 333-276814), which was declared effective on February 12,

2024, and a related base prospectus and prospectus supplement thereunder dated May 19, 2026.

The legal opinion of Loeb & Loeb LLP relating

to the Shares, Warrants and Warrant Shares is filed herewith as Exhibit 5.1.

The foregoing description of the terms and conditions

of the Undewriting Agreement and the Warrant do not purport to be complete and are qualified in its entirety by the full text of

each of such document, copies of which are attached hereto as Exhibits 10.1 and 4.1, respectively, and incorporate by reference

herein.

Item 7.01

Regulation FD Disclosure

On May 19, 2026, the Company issued a press release announcing the

launch of the Offering. On May 20, 2026, the Company issued a press release announcing the pricing of the Offering. Copies of the press

releases are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

The information contained in this Item 7.01 shall

not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific

reference in such a filing.

Item 9.01

Financial Statements and Exhibits

Exhibit Number

Description

4.1

Form of Warrant

5.1

Opinion of Loeb & Loeb LLP

10.1

Underwriting Agreement

23.1

Consent of Loeb & Loeb LLP (contained in Exhibit 5.1)

99.1

Press Release, dated May 19, 2026

99.2

Press Release, dated May 20, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANNOVIS BIO, INC.

Date: May 20, 2026

By:

/s/ Maria Maccecchini

Name:

Maria Maccecchini

Title:

President and Chief Executive Officer

EX-4.1 — EXHIBIT 4.1

EX-4.1

Filename: tm2615162d1_ex4-1.htm · Sequence: 2

Exhibit 4.1

WARRANT TO PURCHASE COMMON STOCK

ANNOVIS BIO, INC.

Warrant Shares: [     ]

Issue Date: May 21, 2026

THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”)

certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the

limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (the “Initial Exercise

Date”) and on or prior to 5:00 p.m. (New York City time) on that date that is six years from the Issue Date (the “Termination

Date”) but not thereafter, to subscribe for and purchase from Annovis Bio, Inc., a Delaware corporation (the “Company”),

up to [     ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s

common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of Common Stock under

this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions. Capitalized terms

used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the “Underwriting

Agreement”), dated May 20, 2026, by and between the Company and Canaccord Genuity LLC.

Section 2. Exercise.

(a)

Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any

time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed

copy submitted by email (or email attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”).

Within one Trading Day following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant

Shares specified in the applicable Notice of Exercise by wire transfer on a United States bank unless the cashless exercise procedure

specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required,

nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding

anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder

has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall

surrender this Warrant to the Company for cancellation within three Trading Days of the date on which the final Notice of Exercise is

delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares

available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal

to the applicable number of Warrant Shares so purchased. The Holder and the Company shall maintain records showing the number of Warrant

Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day

of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the

provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available

for purchase hereunder at any given time may be less than the amount stated on the face hereof.

(b)

Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $2.25, subject to adjustment hereunder

(the “Exercise Price”).

(c)

Cashless Exercise. If at the time of exercise hereof, there is no effective registration statement registering, or the prospectus

contained therein is not available for the issuance or resale of the Warrant Shares to or by the Holder, then this Warrant may also be

exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive

a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice

of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed

and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined

in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder,

either (x) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (y) the Bid Price of the

Common Stock on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s

execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a

Trading Day and is delivered within two hours thereafter (including until two hours after the close of “regular trading hours”

on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such

Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after two

hours following the close of “regular trading hours” on such Trading Day;

(B) = the Exercise Price of this Warrant, as adjusted hereunder; and

(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if

such exercise were by means of a cash exercise rather than a cashless exercise.

If Warrant Shares are issued in such a cashless

exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take

on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section

2(c).

“Bid Price” means, for any

date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading

Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the

Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m.

(New York City time)), (b) if the Common Stock is not then listed on a Trading Market and if the prices for the Common Stock are then

reported on the OTCQB Venture Market (“OTCQB”) or OTCQX Best Market (“OTCQX”), as applicable, the

volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if

the Common Stock is not then listed or quoted for trading on a Trading Market or on OTCQB or OTCQX and if prices for the Common Stock

are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices) (“The

Pink Open Market”), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair

market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority

in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid

by the Company.

“VWAP” means, for any date,

the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading

Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market

on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time)

to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock

for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for

trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency

succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other

cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders

of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall

be paid by the Company.

(d)

Mechanics of Exercise.

Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares issued in connection with an exercise

of the Warrant to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s

balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if

the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of

the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and

otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee,

for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the

Notice of Exercise by the date that is the earlier of (i) one Trading Day after the delivery to the Company of the Notice of Exercise

and (ii) one Trading Day after delivery of the aggregate Exercise Price to the Company (such date, the “Warrant Share Delivery

Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder

of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant

Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant

Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by

the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000

of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10

per Trading Day (increasing to $20 per Trading Day on the third Trading Day after such liquidated damages begin to accrue) for each Trading

Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees

to maintain a transfer agent (the “Transfer Agent”) that is a participant in the FAST program so long as this Warrant

remains outstanding and exercisable.

ii.

Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request

of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new

Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall

in all other respects be identical with this Warrant.

iii.

Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant

to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by providing the Company

with written notice of recission.

iv.

Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available

to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions

of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than a failure that is solely due

to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to

purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock

to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a

“Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s

total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained

by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with such exercise

by (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either

reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such

exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the

Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having

a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrant Shares with an aggregate sale price

giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required

to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect

of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right

to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance

and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant

as required pursuant to the terms hereof.

No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise

of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the number

of Warrant Shares to be issued shall be rounded down to the nearest whole number and the Company shall, at its election, either pay a

cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to

the next whole share.

vi.

Charges, Taxes and Expenses. Issuance and delivery of Warrant Shares shall be made without charge to the Holder for any

issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall

be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed

by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name

of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by

the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental

thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the

Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery

of the Warrant Shares.

(e)

Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have

the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such

issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and

any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates and any other Persons whose beneficial

ownership of the shares of Common Stock would or could be aggregated with the Holder’s for the purposes of Section 13(d) of the

Exchange Act (such Persons, “Attribution Parties”)), would exceed the Beneficial Ownership Limitation (as defined below).

For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution

Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination

is being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised

portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion

of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock

Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the

Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e),

beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated

thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance

with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.

To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in

relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant

is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s

determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates

and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,

and the Company shall have no obligation to verify or confirm the accuracy of such determination (other than to the extent that the information

on the number of outstanding shares of Common Stock is provided by the Company, either directly or through one or more public filings

relied upon by the Holder). In addition, a determination as to any group status as contemplated above shall be determined in accordance

with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining

the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in

(A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public

announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares

of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and

in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common

Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the

Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.

The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by the Holder prior to the issuance of this

Warrant, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares

issuable upon exercise of this Warrant. In the event the Holder holds less than 20% of the number of shares of Common Stock outstanding

prior to giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant, the Holder, upon notice to the

Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership

Limitation in no event exceeds 19.99% (or, upon the election by the Holder prior to the issuance of this Warrant, 9.99%) of the number

of shares of the Common Stock outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant

held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation

will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed

and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any

portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes

or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply

to a successor holder of this Warrant.

Section 3. Certain Adjustments.

(a)

Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or

otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable

in shares of Common Stock (which, for avoidance of doubt, shall not include any Warrant Shares issued by the Company upon exercise of

this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of

reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares

of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction

of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before

such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the

number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price

of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the

record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately

after the effective date in the case of a subdivision, combination or re-classification.

(b)

Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,

issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all (or substantially

all) of the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be

entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired

if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations

on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is

taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders

of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,

that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial

Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership

of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held

in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership

Limitation).

(c)

Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend

or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital

or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,

spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) other than dividends or distributions

subject to Section 3(a) above (a “Distribution”), or other than a reclassification to which Section 3(d) applies, then

at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution

to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable

upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial

Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the

date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,

however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding

the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the

beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution

shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder

exceeding the Beneficial Ownership Limitation).

(d)

Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in

one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (all

of its subsidiaries, taken as a whole) directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other

disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase

offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock

are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of

50% or more of the outstanding Common Stock or 50% or more of the voting power of the outstanding common equity of the Company, (iv) the

Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization

of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for

other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock

or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off,

merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the

outstanding shares of Common Stock or 50% or more of the voting power of the outstanding common equity of the Company (each a “Fundamental

Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant

Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option

of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock

of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the

“Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares

of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation

in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be

appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of

one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration

in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common

Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be

given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.

Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below)

shall, at the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental

Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from

the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised

portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the

Fundamental Transaction is not within the Company’s control, including not approved by the Company’s Board of Directors, Holder

shall only be entitled to receive from the Company or any Successor Entity, the same type or form of consideration (and in the same proportion),

valued at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common

Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination

thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection

with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid

any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor

Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black

Scholes Value” means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV”

function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting

(A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement

of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100

day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day

immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share

used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any

non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on

the Trading Day immediately preceding the public announcement of the applicable Fundamental Transaction (or the consummation of the applicable

contemplated Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to this Section

3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental

Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer

of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder’s election

and (ii) the effective date of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction

in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the

Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written

agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to

such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of

the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable

for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common

Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior

to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock

(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such

shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic

value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in

form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and

be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction

Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power

of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the

same effect as if such Successor Entity had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled

to the benefits of the provisions of this Section 3(d) regardless of whether the Company has sufficient authorized shares of Common Stock

for the issuance of Warrant Shares.

(e)

Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,

as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given

date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

(f)

Notice to Holder.

Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company

shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment

to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii.

Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form)

on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the

Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of

capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with

a Fundamental Transaction, any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its subsidiaries)

is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the

Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,

liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder

at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable

record or effective date hereinafter specified, a notice (unless such information is filed with the Commission, in which case a notice

shall not be required) stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,

rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to

such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,

merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders

of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable

upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice

or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such

notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the

Company or any of the subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report

on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the

effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

Section 4. Transfer of Warrant.

(a)

Transferability. Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder are transferable,

in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written

assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient

to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall

execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations

specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so

assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required

to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall

surrender this Warrant to the Company within three Trading Days of the date on which the Holder delivers an assignment form to the Company

assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase

of Warrant Shares without having a new Warrant issued.

(b)

New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office

of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by

the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division

or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided

or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant

and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

(c)

Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose

(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat

the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,

and for all other purposes, absent actual notice to the contrary.

Section 5. Miscellaneous.

(a)

No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights,

dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly

set forth in Section 3. Without limiting the rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant

to Section 2(c), or to receive cash payments contemplated by Section 2(d)(i) and Section 2(d)(iv) herein, in no event will the Company

be required to net cash settle an exercise of this Warrant.

(b)

Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably

satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,

and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,

shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the

Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant

or stock certificate.

(c)

Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right

required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding

Trading Day.

(d)

Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized

and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of this Warrant.

The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the

duty of issuing the necessary Warrant Shares upon the exercise of this Warrant. The Company will take all such reasonable action as may

be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,

or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares

which may be issued upon the exercise of this Warrant will, upon exercise hereunder and payment for such Warrant Shares in accordance

herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company

in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

Except and to the extent as waived or consented

to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through

any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action,

avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in

the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder

as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the

par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,

(ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable

Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions

or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations

under this Warrant.

Before taking any action which would result in

an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain

all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having

jurisdiction thereof.

(e)

Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall

be determined in accordance with the provisions of the Underwriting Agreement.

(f)

Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,

and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

(g)

Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder

shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other

provision of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with any provision of

this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient

to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,

incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

(h)

Notices. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Notice

of Exercise) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice

or communication is delivered via confirmed email prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day

after the date of transmission, if such notice or communication is delivered via confirmed e-mail on a day that is not a Trading Day or

later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally

recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice

is required to be given, if by hand delivery. The addresses and e-mail addresses for such communications shall be:

If to the Company:

Annovis Bio, Inc.

101 Lindenwood Drive, Suite 225,

Malvern, PA 19355

Attention: Chief Executive Officer

Email: [***]

With copy to:

Loeb & Loeb LLP

345 Park Avenue,

New York, NY 10154

Attention: Joan Guilfoyle

Email: [***]

If to the Holder, to its address or e-mail address on the books and

records of the Company.

(i)

(i) Warrant Agent. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10) days’ notice

to the Holder, the Company may appoint a new warrant agent; provided, that if the Company enters into a warrant agency agreement

with any such new warrant agent and the terms of any such warrant agency agreement conflicts with the terms of this Warrant, the terms

of this Warrant shall prevail. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting

from any consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new

warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent

under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant

agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

(j)

Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant

to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the

Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company

or by creditors of the Company.

(k)

Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,

will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate

compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to

assert the defense in any action for specific performance that a remedy at law would be adequate.

(l)

Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby

shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted

assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and

shall be enforceable by the Holder or holder of Warrant Shares.

(m)

Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,

on the one hand, and the Holder of this Warrant, on the other hand.

(n)

Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and

valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision

shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining

provisions of this Warrant.

(o)

Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be

deemed a part of this Warrant.

**************************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this

Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

Annovis Bio, Inc.

By:

Name:

Title:

NOTICE OF EXERCISE

TO: ANNOVIS BIO, INC.

(1)       The

undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant, and tenders

herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2)           Payment

shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

[ ] if permitted the cancellation of such number of Warrant

Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum

number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

(3)           Please

issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

The Warrant Shares shall be delivered to the following

DWAC Account Number:

[SIGNATURE OF HOLDER]

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required

information. Do not use this form to exercise the Warrant to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced

thereby are hereby assigned to

Name:

(Please Print)

Address:

(Please Print)

Phone Number:

Email Address:

Dated:

Holder’s Signature:

Holder’s Address:

EX-5.1 — EXHIBIT 5.1

EX-5.1

Filename: tm2615162d1_ex5-1.htm · Sequence: 3

Exhibit 5.1

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Main   212.407.4000

Fax      212.407.4990

May 20, 2026

Annovis Bio, Inc.

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

Ladies and Gentlemen:

We have acted as counsel to Annovis Bio, Inc., a Delaware corporation

(the “Company”), in connection with the offer and sale by the Company of (i) an aggregate of 7,895,000 shares (the “Shares”)

of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), and (ii) accompanying common stock

warrants to purchase up to an aggregate of 7,105,500 shares of Common Stock (the “Warrants” and the shares of Common Stock

issuable upon exercise of the Warrants, the “Warrant Shares”), in each case pursuant to that certain Underwriting Agreement,

by and between the Company and Canaccord Genuity LLC, as underwriter, dated May 20, 2026 (the “Underwriting Agreement”). The

Common Stock, Warrants and Warrant Shares are referred to herein as the “Securities.” The Securities are being offered for

sale pursuant to the Company’s registration statement on Form S-3, as amended (File No. 333-276814) (the “Registration

Statement”), filed with the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933,

as amended (the “Securities Act”) and the rules and regulations promulgated thereunder, the base prospectus, dated February

12, 2024 (the “Base Prospectus”), and the prospectus supplement, dated May 19, 2026, filed pursuant to Rule 424(b)(5) under

the Securities Act (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”). Terms

not defined herein shall have the same meaning as in the Underwriting Agreement.

In connection with the

opinions set forth below, we have examined the Registration Statement, the General Disclosure Package, the Prospectus, the Underwriting

Agreement and the form of Warrant. We have also examined originals or copies, certified or otherwise identified to our satisfaction, of

the Company’s amended and restated certificate of incorporation and amended and restated bylaws, and such corporate records of the

Company and other certificates and documents of officials of the Company, public officials and others as we have deemed appropriate for

purposes of this letter. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals,

and the conformity to authentic original documents of all copies submitted to us as conformed and certified or reproduced copies.

Based upon the foregoing and

subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that:

1. The Shares have been duly

authorized for issuance, and, when issued and paid for in accordance with the terms and conditions of the Underwriting Agreement, the

Registration Statement and the Prospectus, will be validly issued, fully paid and non-assessable.

2. The Warrants have been

duly authorized for issuance and when executed and delivered in accordance with the terms and conditions of the Underwriting Agreement,

the Registration Statement and the Prospectus, will constitute valid and legally binding obligations of the Company, enforceable against

the Company in accordance with their terms.

3. The Warrant Shares have

been duly authorized for issuance and if, as, and when the Warrant Shares are issued and delivered by the Company upon exercise of the

Warrants in accordance with the terms thereof, including, without limitation, the payment in full of applicable consideration, will be

validly issued, fully paid and non-assessable

The opinions we express above

are based upon a review only of those laws, statutes, rules, ordinances and regulations which, in our experience, a securities lawyer

who is a member of the bar of the State of New York and practicing before the Commission exercising customary professional diligence would

reasonably recognize as being applicable to the foregoing transactions.

The opinions set forth in

paragraph 2 above are subject to (i) the effect of any applicable bankruptcy, insolvency, reorganization, moratorium or similar law relating

to or affecting creditors’ rights generally (including, without limitation, fraudulent conveyance laws) and (ii) the effect of general

principles of equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible

unavailability of specific performance or injunctive relief, regardless of whether considered in a proceeding in equity or at law.

We express no opinion as to

the enforceability of (i) provisions that relate to choice of law, forum selection or submission to jurisdiction (including, without limitation,

any express or implied waiver of any objection to venue in any court or of any objection that a court is an inconvenient forum) to the

extent that the validity, binding effect or enforceability of any such provision is to be determined by any court other than a state court

of the State of New York and (ii) waivers by the Company of any statutory or constitutional rights or remedies. We draw your attention

to the fact that, under certain circumstances, the enforceability of terms to the effect that provisions may not be waived or modified

except in writing may be limited.

The opinions we express herein

are limited to matters involving the internal laws of the State of New York and the Delaware General Corporation law.

This opinion has been prepared

solely for use in connection with the transmitting for filing of the Prospectus Supplement on the date of this letter and may be relied

upon for no other purpose without our prior written consent.

We hereby consent to the filing

of this letter with the Commission as an exhibit to the Current Report on Form 8-K to be filed by the Company in connection with the issuance

and sale of the Shares, the Warrants and the Warrant Shares in accordance with the requirements of Item 601(b)(5) of Regulation S-K under

the Securities Act and to the reference to our firm therein and in the Prospectus under the caption “Legal Matters.” In giving

such consent, we do not thereby admit that this firm is within the category of persons whose consent is required under Section 7 of the

Securities Act or the rules and regulations of the Commission under such Section.

Very truly yours,

/s/ Loeb & Loeb LLP

Loeb & Loeb LLP

EX-10.1 — EXHIBIT 10.1

EX-10.1

Filename: tm2615162d1_ex10-1.htm · Sequence: 4

Exhibit 10.1

ANNOVIS BIO, INC.

7,895,000 Shares of Common Stock

Warrants to Purchase 7,105,500 Shares of Common

Stock

UNDERWRITING AGREEMENT

May 20, 2026

CANACCORD GENUITY LLC

Penn 1, One Pennsylvania Plaza, Suite 2900

New York, NY 10119

Dear Sirs and Madams:

INTRODUCTORY. Annovis Bio, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms

of this Underwriting Agreement (this “Agreement”), to the underwriter named in Schedule A hereto (the “Underwriter”),

(i) an aggregate of 7,895,000 shares (the “Shares”) of common stock, $0.0001 par value per share (the “Common

Stock”), of the Company and (ii) accompanying Warrants, substantially in the form of Annex A hereto, to purchase an aggregate

of 7,105,500 shares of Common Stock with an exercise price equal to $2.25 per share (the “Accompanying Warrants” and

such Accompanying Warrants and Shares being hereinafter collectively referred to as the “Securities”). As used herein,

“Warrant Shares” means the shares of Common Stock issuable upon exercise of the Accompanying Warrants.

REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company represents and warrants to the Underwriter, as of the date hereof and

as of the Closing Date (as defined below), and agrees with the Underwriter, that:

(a)

Registration Statement. A registration statement of the Company on Form S-3 (File No. 333-276814) (including all amendments

thereto, the “Initial Registration Statement”) in respect of the Securities has been filed with the Securities and

Exchange Commission (the “Commission”) pursuant to Rule 415 under the Securities Act of 1933, as amended (the “Securities

Act”), and the rules and regulations of the Commission thereunder (the “Rules and Regulations”). The Company

represents and warrants that it meets the requirements for the use of Form S-3 set forth in General Instruction I.A of Form S-3 and that

the proposed offering of the Securities may be made pursuant to General Instruction I.B.1 of Form S-3. The Initial Registration Statement

and any post-effective amendment thereto, each in the form, excluding exhibits thereto, heretofore delivered or made available to you,

have been declared effective by the Commission in such form and meet the requirements of the Securities Act and the Rules and Regulations.

The Initial Registration Statement and any post-effective amendment thereto, each in the form excluding exhibits heretofore delivered

or made available to you have been declared effective by the Commission in such form and meet the requirements of the Securities Act and

the Rules and Regulations. Other than (i) the Initial Registration Statement, (ii) a registration statement, if any, increasing the size

of the offering filed pursuant to Rule 462(b) under the Securities Act and the Rules and Regulations (a “Rule 462(b) Registration

Statement”), (iii) any Preliminary Prospectus (as defined below), (iv) the Prospectus (as defined below) contemplated by this

Agreement to be filed pursuant to Rule 424(b) of the Rules and Regulations in accordance with Section 4(a) hereof and (v) any Issuer Free

Writing Prospectus (as defined below), no other document with respect to the offer and sale of the Securities has heretofore been filed

with the Commission. No stop order suspending the effectiveness of the Initial Registration Statement, any post-effective amendment thereto

or the Rule 462(b) Registration Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section 8A of the

Securities Act has been initiated or, to the Company’s knowledge, threatened by the Commission (any preliminary prospectus included

in the Initial Registration Statement or filed with the Commission pursuant to Rule 424 of the Rules and Regulations is hereinafter called

a “Preliminary Prospectus”). The Initial Registration Statement including all exhibits thereto and including the information

contained in the Prospectus filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations and deemed by virtue of Rule

430A, Rule 430B and Rule 430C, as applicable, under the Securities Act to be part of the Initial Registration Statement at the time it

became effective is hereinafter collectively called the “Registration Statement.” If the Company has filed a Rule 462(b)

Registration Statement, then any reference herein to the term “Registration Statement” shall be deemed to include such Rule

462 Registration Statement. The base prospectus included in the Initial Registration Statement at the time of effectiveness thereof (the

“Base Prospectus”), as supplemented by the final prospectus supplement relating to the offer and sale of the Securities,

in the form filed pursuant to and within the time limits described in Rule 424(b) under the Rules and Regulations, is hereinafter called

the “Prospectus.”

Any reference herein to the Registration Statement,

Base Prospectus, Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference

therein. Any reference to any amendment or supplement to any Preliminary Prospectus or the Prospectus shall be deemed to refer to and

include any documents filed after the date of such Preliminary Prospectus or the Prospectus under the Securities Exchange Act of 1934,

as amended (the “Exchange Act”), and incorporated by reference in such Preliminary Prospectus or Prospectus, as the

case may be. Any reference to (i) the Registration Statement shall be deemed to refer to and include the annual report on Form 10-K of

the Company for the last completed fiscal year of the Company for which an annual report on Form 10-K has been filed under Section 13(a)

or 15(d) of the Exchange Act prior to the date hereof and (ii) the effective date of such Registration Statement shall be deemed to refer

to and include the date such Registration Statement became effective and, if later, the date such Form 10-K was so filed. Any reference

to any amendment to the Registration Statement shall be deemed to refer to and include any annual report of the Company filed pursuant

to Section 13(a) or 15(d) of the Exchange Act after the date of this Agreement that is incorporated by reference in the Registration Statement.

(b)

General Disclosure Package. As of the Applicable Time (as defined below) and as of the Closing Date, neither (i) the General

Use Free Writing Prospectus(es) (as defined below) issued at or prior to the Applicable Time, and the Pricing Prospectus (as defined below)

and the information included on Schedule C hereto, all considered together (collectively, the “General Disclosure Package”),

(ii) any individual Limited Use Free Writing Prospectus (as defined below), nor (iii) the bona fide electronic roadshow (as defined in

Rule 433(h)(5) of the Rules and Regulations), when considered together with the General Disclosure Package, included or will include any

untrue statement of a material fact or omitted or will omit to state a material fact necessary in order to make the statements therein,

in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representations

or warranties as to information contained in or omitted from the Pricing Prospectus or any Issuer Free Writing Prospectus (as defined

below), in reliance upon, and in conformity with, written information furnished to the Company through the Underwriter specifically for

inclusion therein, which information the parties hereto agree is limited to the Underwriter’s Information (as defined herein). As

used in this paragraph (b) and elsewhere in this Agreement:

“Applicable Time”

means 7:15 a.m., New York time, on the date of this Agreement or such other time as agreed to by the Company and the Underwriter.

“Pricing Prospectus”

means the Base Prospectus, as amended and supplemented immediately prior to the Applicable Time, including any document incorporated

by reference therein and any prospectus supplement deemed to be a part thereof.

“Issuer Free Writing

Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the Rules and Regulations relating

to the Securities in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained

in the Company’s records pursuant to Rule 433(g) of the Rules and Regulations.

“General Use Free

Writing Prospectus” means any Issuer Free Writing Prospectus that is identified on Schedule B to this Agreement.

“Limited Use Free

Writing Prospectuses” means any Issuer Free Writing Prospectus that is not a General Use Free Writing Prospectus.

“Written Testing-the-Waters

Communication” means any Testing-the-Waters Communication (as defined below) that is a written communication within the meaning

of Rule 405 of the Rules and Regulations.

(c)

No Stop Orders; No Material Misstatements. No order preventing or suspending the use of any Preliminary Prospectus, any

Issuer Free Writing Prospectus or the Prospectus relating to the proposed offering of the Securities has been issued by the Commission,

and no proceeding for that purpose or pursuant to Section 8A of the Securities Act has been instituted or threatened by the Commission,

and each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Securities

Act and the Rules and Regulations, and did not contain an untrue statement of a material fact or omit to state a material fact required

to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading;

provided, however, that the Company makes no representations or warranties as to information contained in or omitted from any Preliminary

Prospectus, in reliance upon, and in conformity with, written information furnished to the Company through the Underwriter specifically

for inclusion therein, which information the parties hereto agree is limited to the Underwriter’s Information.

(d)

Registration Statement and Prospectus Contents. At the respective times the Registration Statement and any amendments thereto

became or become effective and at the Closing Date, the Registration Statement and any amendments thereto conformed and will conform in

all material respects to the requirements of the Securities Act and the Rules and Regulations and did not and will not contain any untrue

statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein

not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement

thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities

Act and the Rules and Regulations and did not and will not contain an untrue statement of a material fact or omit to state a material

fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading; provided,

however, that the foregoing representations and warranties in this paragraph (d) shall not apply to information contained in or omitted

from the Registration Statement or the Prospectus, or any amendment or supplement thereto, in reliance upon, and in conformity with, written

information furnished to the Company through the Underwriter specifically for inclusion therein, which information the parties hereto

agree is limited to the Underwriter’s Information.

(e)

Issuer Free Writing Prospectus. Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through

the completion of the public offer and sale of the Securities or until any earlier date that the Company notified or notifies the Underwriter

as described in Section 4(f), did not, does not and will not include any information that conflicted, conflicts or will conflict

with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus, including any document incorporated

by reference therein and any prospectus supplement deemed to be a part thereof that has not been superseded or modified, or included or

would include an untrue statement of a material fact or omitted or would omit to state a material fact required to be stated therein or

necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading provided, however,

that the foregoing representations and warranties in this paragraph (e) shall not apply to information contained in or omitted from

the Registration Statement, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, in reliance upon, and in

conformity with, written information furnished to the Company through the Underwriter specifically for inclusion therein, which information

the parties hereto agree is limited to the Underwriter’s Information.

(f)

Documents Incorporated by Reference. The documents incorporated by reference in the Prospectus, when they became effective

or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act or

the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and none of such documents contained any untrue

statement of a material fact or omitted to state any material fact required to be stated therein, or necessary to make the statements

therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated

by reference in the Prospectus, when such documents are filed with Commission will conform in all material respects to the requirements

of the Securities Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and will not contain

any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements

therein, in the light of the circumstances under which they were made, not misleading.

(g)

Distribution of Offering Materials. The Company has not, directly or indirectly, distributed and will not distribute any

offering material in connection with the offering and sale of the Securities other than any Preliminary Prospectus, the Prospectus and

other materials, if any, permitted under the Securities Act and consistent with Section 4(c) below. The Company will file with the Commission

all Issuer Free Writing Prospectuses (other than a “road show” as described in Rule 433(d)(8) of the Rules and Regulations)

in the time and manner required under Rules 163(b)(2) and 433(d) of the Rules and Regulations.

(h)             Not

an Ineligible Issuer. At the time of filing the Initial Registration Statement, any Rule 462(b) Registration Statement and any

post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an

“ineligible issuer,” as defined in Rule 405 of the Rules and Regulations.

(i)

Testing the Waters Communications. The Company (a) has not alone engaged in any Testing-the-Waters Communication other

than Testing-the-Waters Communications with the consent of the Underwriter with entities that are qualified institutional buyers within

the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501 under

the Securities Act and (b) has not authorized anyone to engage in Testing-the-Waters Communications. The Company has not distributed

any Written Testing-the-Waters Communications other than those listed on Schedule D hereto. “Testing-the-Waters Communication”

means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.

(j)

Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(k)

The Securities. The Shares to be issued and sold by the Company to the Underwriter hereunder have been duly authorized

and, when issued and delivered by the Company against payment therefor as provided herein, will be validly issued, fully paid and non-assessable

and will conform to the descriptions thereof in the Registration Statement, the General Disclosure Package and the Prospectus; and the

issuance of the Shares is not subject to any preemptive or similar rights. The Accompanying Warrants have been duly authorized by the

Company and, when executed and delivered by the Company, will be valid and binding agreements of the Company, enforceable against the

Company in accordance with their respective terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization,

moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. The

Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Accompanying Warrants in a number sufficient

to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the Accompanying Warrants in

accordance therewith against payment of the exercise price as provided therein, will be validly issued, fully paid and nonassessable,

and the issuance of the Warrant Shares is not subject to any preemptive or similar rights.

(l)

No Material Adverse Change. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package

and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the General Disclosure

Package and the Prospectus: (i) there has been no material adverse change in the condition (financial or otherwise), assets, rights,

operations, business, management or prospects of the Company (any such change is called a “Material Adverse Change”)

or any development involving a prospective material adverse change, which, individually or in the aggregate, has had or would reasonably

be expected to result in a Material Adverse Change; (ii) the Company has not incurred any material liability or obligation, indirect,

direct or contingent, not in the ordinary course of business nor entered into any material transaction or agreement not in the ordinary

course of business; and (iii) there has been no dividend or distribution of any kind declared, paid or made by the Company on any

class of capital stock or repurchase or redemption by the Company of any class of capital stock.

(m)

Independent Accountants. Ernst & Young LLP, who have certified certain financial statements (which term as used in this

Agreement includes the related notes thereto) of the Company filed with the Commission or incorporated or included, as applicable, by

reference in the Registration Statement, the General Disclosure Package and the Prospectus, is (i) an independent registered public accounting

firm as required by the Securities Act, the Exchange Act, and the rules of the Public Company Accounting Oversight Board (“PCAOB”),

(ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under

the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or

revoked and, to the knowledge of the Company, who has not requested such registration to be withdrawn.

(n)

Preparation of the Financial Statements. The consolidated financial statements of the Company, together with related notes

and schedules as incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus, present fairly

the financial position and the results of operations and cash flows of the Company, at the indicated dates and for the indicated periods.

Such financial statements and related schedules have been prepared in accordance with U.S. generally accepted principles of accounting,

consistently applied throughout the periods involved, except as disclosed therein, and all adjustments necessary for a fair presentation

of results for such periods have been made. The summary financial and statistical data included or incorporated by reference in the Registration

Statement, the General Disclosure Package and the Prospectus present fairly the information shown therein and such data has been compiled

on a basis consistent with the financial statements presented therein and the books and records of the Company. The statistical, industry-related

and market-related data included or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus

are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and the Company

has obtained the written consent to the use of such data from such sources to the extent required. The financial data set forth or incorporated

by reference in the Registration Statement, the General Disclosure Package and Prospectus fairly present the information shown therein

and such data has been compiled on a basis consistent with the financial statements presented therein and the books and records of the

Company.

(o)

XBRL. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration

Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has

been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

(p)

Incorporation and Good Standing of the Company. The Company is a corporation duly incorporated and validly existing under

the laws of the State of Delaware and is in good standing under such laws. The Company has requisite corporate power to carry on its

business as described in the Prospectus. The Company is duly qualified to transact business and is in good standing in all jurisdictions

in which the conduct of its business requires such qualification; except where the failure to be so qualified or to be in good standing

would not result in a Material Adverse Change.

(q)

Subsidiaries. The Company does not currently own or control, directly or indirectly, any interest in any other corporation,

partnership, trust, joint venture, limited liability company, association, or other business entity.

(r)

Capital Stock Matters. The Common Stock conforms in all material respects to the description thereof contained in the Registration

Statement, the General Disclosure Package and the Prospectus. The form of certificates for the Common Stock conforms to the corporate

law of the jurisdiction of the Company’s incorporation. All of the issued and outstanding shares of Common Stock have been duly

authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with federal and state securities laws.

None of the outstanding shares of Common Stock were issued in violation of any preemptive rights, rights of first refusal or other similar

rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights,

rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for,

any capital stock of the Company other than those disclosed in or in a document filed as an exhibit to or incorporated by reference into

the Registration Statement, the General Disclosure Package and the Prospectus.

(s)

Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. The Company is not (i) in

breach or violation of its certificate or bylaws, (ii) in breach of or in default (or, with the giving of notice or lapse of time

or both, would be in default) (“Default”) under any indenture, mortgage, loan or credit agreement, deed of

trust, note, contract, franchise, lease or other agreement, obligation, condition, covenant or instrument to which the Company is a party

or by which it may be bound or to which any of the property or assets of the Company is subject (each, an “Existing Instrument”),

or (iii) in violation of any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative

agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any of its properties,, except, with

respect to clauses (ii) and (iii) only, for such breaches, violations or Defaults that would not, individually or in the aggregate,

result in a Material Adverse Change. The Company’s execution, delivery and performance of this Agreement and the Accompanying Warrants,

and consummation of the transactions contemplated hereby or thereby or by the Registration Statement, the General Disclosure Package

and the Prospectus (including the issuance and sale of the Securities and the use of the proceeds from the sale of the Securities as

described in the Prospectus under the caption “Use of Proceeds”) (i) will not result in any breach or violation of the

certificate of incorporation or bylaws of the Company, (ii) will not conflict with or constitute a breach of, or Default or a Debt

Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge, claim or encumbrance

upon any property or assets of the Company pursuant to, or require the consent of any other party to, any Existing Instrument, and (iii) will

not result in any violation of any statute, law, rule, regulation, judgment, order or decree applicable to the Company of any court,

regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over the Company or any

of its properties, except, with respect to clauses (ii) and (iii) only, for such conflicts, breaches, Defaults, Debt Repayment Triggering

Events or violations that would not, individually or in the aggregate, result in a Material Adverse Change. As used herein, a “Debt

Repayment Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time or

both would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf),

issued by the Company, the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company.

Each approval, consent, order, authorization, designation, declaration or filing by or with any regulatory, administrative or other governmental

body necessary in connection with the execution and delivery by the Company of this Agreement and the Accompanying Warrants, and the

performance of the Company of the transactions herein or therein contemplated has been obtained or made and is in full force and effect,

except such additional steps as may be required by the bylaws and rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”)

or the New York Stock Exchange (the “Exchange”) in connection with the purchase and distribution of the Securities

by the Underwriter and the listing of the Shares and the Warrant Shares on the Exchange.

(t)

No Material Actions or Proceedings; Labor Disputes. There is no action, suit, claim or proceeding pending or, to the knowledge

of the Company, threatened against the Company before any court or administrative agency or otherwise (i) that is required to be

described in the Registration Statement, the General Disclosure Package or the Prospectus and are not so described or (ii) which,

if determined adversely to the Company, would reasonably be expected to result in a Material Adverse Change or prevent the consummation

of the transactions contemplated hereby, except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus.

The aggregate of all pending legal or governmental proceedings to which the Company is a party or of which any of its property or assets

is the subject which are not described in the Prospectus, including ordinary routine litigation incidental to the business, could not

reasonably be expected to result in a Material Adverse Change. No labor dispute with the employees of the Company exists or, to the Company’s

knowledge, is threatened or imminent, and the Company is not aware of any existing or imminent labor dispute by the employees of any of

its principal suppliers, contractors or customers, that would, individually or in the aggregate, reasonably be expected to result in a

Material Adverse Change. None of the employees of the Company is represented by a union and, to the knowledge of the Company, no union

organizing activities are taking place. The Company has not violated any federal, state or local law or foreign law relating to the discrimination

in hiring, promotion or pay of employees, nor any applicable wage or hour laws, or the rules and regulations thereunder, or analogous

foreign laws and regulations, which might, individually or in the aggregate, result in a Material Adverse Change.

(u)

All Necessary Permits, etc. The Company has all material licenses, certifications, permits, franchises, approvals, clearances

and other regulatory authorizations (“Permits”) from governmental authorities as are necessary to (i) conduct

its business as currently conducted and (ii) own, lease and operate its properties in the manner described in the Registration Statement,

the General Disclosure Package and the Prospectus. There is no claim or proceeding pending or, to the knowledge of the Company, threatened,

involving the status of or sanctions under any of the Permits. The Company has fulfilled and performed all of its material obligations

with respect to the Permits, and the Company is not aware of the occurrence of any event which allows, or after notice or lapse of time

would allow, the revocation, termination, or other impairment of the rights of the Company under such Permit.

(v)

Tax Law Compliance. All United States federal income tax returns of the Company required by law to be filed have been filed

or extensions thereof have been requested, and all taxes shown by such returns or otherwise assessed, which are due and payable, have

been paid, except assessments that are being contested in good faith and as to which adequate reserves have been provided. The Company

has filed all other tax returns that are required to have been filed by it pursuant to applicable foreign, state, provincial, local or

other law except insofar as the failure to file such returns would not result in a Material Adverse Change, and has paid all taxes due

pursuant to such returns or pursuant to any assessment received by the Company, except for such taxes, if any, as are being contested

in good faith and as to which adequate reserves have been provided and except for such taxes or assessments the nonpayment of which would

not, individually or in the aggregate, result in a Material Adverse Change. The charges, accruals and reserves on the books of the Company

in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments

for additional tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse

Change. All material taxes which the Company is required by law to withhold or to collect for payment have been duly withheld and collected

and have been paid to the appropriate governmental authority or agency or have been accrued, reserved against and entered on the books

of the Company. There are no transfer taxes or other similar fees or charges under Federal law or the laws of any state, or any political

subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement or the issuance by the Company

or sale of the Securities.

(w)

Company Not an “Investment Company”. The Company is not, and will not be, either after receipt of payment for

the Securities or after the application of the proceeds therefrom as described under “Use of Proceeds” in the Registration

Statement, the General Disclosure Package or the Prospectus, required to register as an “investment company” under the Investment

Company Act of 1940, as amended.

(x)

Insurance. Except as otherwise described in the Registration Statement, the General Disclosure Package and the Prospectus,

the Company carries, or is covered by, insurance in such amounts and covering such risks as is generally considered adequate for the conduct

of its business and the value of its properties and as is customary for companies engaged in similar industries. All policies of insurance

insuring the Company or its business, assets, employees, officers and directors are in full force and effect, and the Company is in compliance

with the terms of such policies in all material respects. There are no claims by the Company under any such policy or instrument as to

which an insurance company is denying liability or defending under a reservation of rights clause. The Company has no reason to believe

that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable

coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would

not result in a Material Adverse Change.

(y)

No Price Stabilization or Manipulation. Neither the Company, nor any of its directors, officers or, to the knowledge of

the Company, controlling persons has taken, directly or indirectly, any action designed to or that might reasonably be expected to cause

or result in the stabilization or manipulation of the price of the Common Stock or of any “reference security” (as defined

in Rule 100 of Regulation M under the Exchange Act (“Regulation M”)) with respect to the Common Stock, whether to facilitate

the sale or resale of the Securities or otherwise, and has taken no action which would directly or indirectly violate Regulation M.

(z)

Related Party Transactions. There are no business relationships or related-party transactions involving the Company required

to be described in the Registration Statement, the General Disclosure Package or the Prospectus which have not been described (or described

in documents incorporated by reference therein) as required.

(aa)

Exchange Act Compliance. The documents incorporated or deemed to be incorporated by reference in the Registration Statement,

the General Disclosure Package, the Prospectus or any amendment or supplement thereto, at the time they were or hereafter are filed with

the Commission under the Exchange Act, complied and will comply in all material respects with the requirements of the Exchange Act, and,

when read together with the other information in the Registration Statement, the General Disclosure Package and the Prospectus, will not

contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the

fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were

made, not misleading.

(bb)

Compliance with Environmental Laws. To its knowledge, the Company is not in violation of any statute, any rule, regulation,

decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous

chemicals, toxic substances or radioactive and biological materials or relating to the protection or restoration of the environment or

human exposure to hazardous chemicals, toxic substances or radioactive and biological materials (collectively, “Environmental

Laws”). The Company neither owns nor, to its knowledge, operates any real property contaminated with any substance that

is subject to any Environmental Laws, is not liable for any off-site disposal or contamination pursuant to any Environmental Laws, nor

is it subject to any claim relating to any Environmental Laws, which violation, contamination, liability or claim would individually or

in the aggregate result in a Material Adverse Change; and the Company is not aware of any pending investigation which might lead to such

a claim.

(cc)

Intellectual Property. To the Company’s knowledge, except as otherwise disclosed in the Registration Statement, the

General Disclosure Package and the Prospectus, the Company owns, or has obtained valid and enforceable licenses for, the patent applications,

patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration

Statement, the General Disclosure Package and the Prospectus as being owned or licensed by them (collectively, “Intellectual

Property”). To the Company’s knowledge, except as otherwise disclosed in the Registration Statement, the General Disclosure

Package and the Prospectus, the conduct of its businesses in the manner described in the Registration Statement and the Prospectus does

not and will not infringe or misappropriate rights of a third party, except any such infringement or misappropriation as would not, individually

or in the aggregate, result in a Material Adverse Change. To the Company’s knowledge, the Intellectual Property owned by the Company

has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company’s

knowledge, except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus: (i) there are

no third parties who have rights to any Intellectual Property, except for rights of third-party licensors with respect to Intellectual

Property that are disclosed in the Registration Statement, the General Disclosure Package and the Prospectus as licensed to the Company;

and (ii) there is no infringement by third parties of any Intellectual Property except any such infringement as would not, individually

or in the aggregate, result in a Material Adverse Change. Except as otherwise disclosed in the Registration Statement, the General Disclosure

Package and the Prospectus, there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by

others: (A) challenging the Company’s rights in or to any Intellectual Property; (B) challenging the validity, enforceability or

scope of any Intellectual Property; or (C) asserting that the Company infringes or otherwise violates, or would, upon the commercialization

of any product or service described in the Registration Statement, the General Disclosure Package or the Prospectus as under development,

infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary intellectual property

rights of others, except in each case (A), (B), and (C), any such action, suit, proceeding or claim would not, individually or in the

aggregate, result in a Material Adverse Change. To the Company’s knowledge, except as otherwise disclosed in the Registration Statement,

the General Disclosure Package and the Prospectus, the Company has complied with the material terms of each agreement pursuant to which

Intellectual Property has been licensed to the Company, and all such agreements are in full force and effect, except to the extent anything

inconsistent with the foregoing would not, individually or in the aggregate, result in a Material Adverse Change. To the Company’s

knowledge, except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there are no

material defects in any of the patents or patent applications included in the Intellectual Property. To the Company’s knowledge,

except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company has taken

all reasonable steps to protect, maintain and safeguard its Intellectual Property, including the execution of appropriate nondisclosure,

confidentiality agreements and invention assignment agreements and invention assignments with their employees, and no employee of the

Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement,

nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to the Company

Intellectual Property and such employee’s employment with the Company, except anything inconsistent with the foregoing that would

not, individually or in the aggregate, result in a Material Adverse Change. To the Company’s knowledge, except as otherwise disclosed

in the Registration Statement, the General Disclosure Package and the Prospectus, the Company’s patent counsel has complied or is

in the process of complying with its duty of candor and good faith as required by the United States Patent and Trademark Office during

the prosecution of the United States patents and patent applications included in the Company owned Intellectual Property. To the Company’s

knowledge, except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, none of the

Company owned Intellectual Property employed by the Company has been obtained or is being used by the Company in violation of any contractual

obligation binding on the Company or any of its officers, directors or employees or otherwise in violation of the rights of any persons,

except anything inconsistent with the foregoing that would not, individually or in the aggregate, result in a Material Adverse Change.

(dd)

Brokers. Other than the Underwriter, there is no broker, finder or other party that is entitled to receive from the Company

any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

(ee)

No Outstanding Loans or Other Indebtedness. There are no outstanding loans, advances (except normal advances for business

expenses in the ordinary course of business) or guarantees of indebtedness by the Company to or for the benefit of any of the officers

or directors of the Company or any of their respective family members, except as disclosed in the Registration Statement, the General

Disclosure Package and the Prospectus. The Company has not directly or indirectly extended or maintained credit, arranged for the extension

of credit, or renewed an extension of credit, in the form of a personal loan to or for any director or executive officer of the Company.

(ff)

No Reliance. The Company has not relied upon the Underwriter or legal counsel for the Underwriter for any legal, tax or

accounting advice in connection with the offering and sale of the Securities.

(gg)

Broker-Dealer Status. Neither the Company nor any of its related entities (i) is required to register as a “broker”

or “dealer” in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more

intermediaries, controls or is a “person associated with a member” or “associated person of a member” (within

the meaning of Article I of the NASD Manual administered by FINRA). To the Company’s knowledge, there are no affiliations or associations

between any member of FINRA and any of the Company’s officers, directors or 10% or greater security holders, except as set forth

in the Registration Statement, the General Disclosure Package and the Prospectus. All of the information (including, but not limited to,

information regarding affiliations, security ownership and trading activity) provided to the Underwriter or its counsel by the Company,

its officers and directors and the holders of any securities (debt or equity) or warrants, options or rights to acquire any securities

of the Company in connection with the filing to be made and other supplemental information to be provided to FINRA pursuant to Rule 5110

of FINRA in connection with the transactions contemplated by this Agreement is true, complete and correct, and copies of any Company

filings required to be filed with FINRA have been filed with the Commission or delivered to the Underwriter for filing with FINRA.

(hh)

Compliance with Laws. The Company has not been advised, and has no reason to believe, that it is not conducting business

in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, except where failure

to be so in compliance would not result in a Material Adverse Change. The Company maintains and periodically reviews written policies

and procedures reasonably designed to keep the Company and its employees conduct in connection with the Company’s business in compliance

with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business.

(ii)

Certain Regulations. The studies, tests and clinical trials conducted by or on behalf of the Company and its subsidiaries

were and, if still pending, are being conducted in compliance with experimental protocols, procedures and controls pursuant to accepted

professional scientific standards and all applicable laws and authorizations, including, without limitation, the Federal Food, Drug and

Cosmetic Act and the rules and regulations promulgated thereunder, except where the failure to be in compliance could not reasonably be

expected to result in a Material Adverse Change; the descriptions of the results of such studies, tests and clinical trials contained

in the Registration Statement, the General Disclosure Package and the Prospectus are accurate and complete in all material respects and

fairly present the data derived from such studies, tests and clinical trials; except to the extent disclosed in the Registration Statement,

the General Disclosure Package and the Prospectus, to the knowledge of the Company, there are no studies, tests or clinical trials, the

results of which the Company believes reasonably call into question the study, test, or clinical trial results described or referred to

in the Registration Statement, the General Disclosure Package and the Prospectus when viewed in the context in which such results are

described; and, except to the extent disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company

has not received any notices or correspondence from any applicable governmental authority requiring the termination, suspension or material

modification of any studies, tests or clinical trials conducted by or on behalf of the Company.

(jj)

FDA Regulations. The Company: (i) is and at all times has been in compliance with all statutes, rules, or regulations, including

but not limited to those administered by the United States Food and Drug Administration (“FDA”), the European Medicines

Agency (“EMA”) and similar governmental authorities applicable to the ownership, testing, development, manufacture,

packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of

any products being developed, manufactured or distributed by the Company (“Applicable Laws”), except as could not,

individually or in the aggregate, reasonably be expected to result in a Material Adverse Change; (ii) has not received any warning letter

or other correspondence or notice from the FDA, EMA or any other governmental authority alleging or asserting noncompliance with any Applicable

Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any

such Applicable Laws (“Authorizations”); (iii) possess all material Authorizations and such Authorizations are valid

and in full force and effect and are not in material violation of any term of any such Authorizations; (iv) have not received notice of

any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental authority

or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and have no knowledge

that any such governmental authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation

or proceeding; (v) have not received notice that any governmental authority has taken, is taking or intends to take action to limit, suspend,

modify or revoke any Authorizations and have no knowledge that any such governmental authority is considering such action; (vi) have filed,

obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements

or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications,

records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented

by a subsequent submission); and (vii) have not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be

initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert, or other notice or action relating to the

alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no

third party has initiated, conducted or intends to initiate any such notice or action.

(kk)

Sarbanes–Oxley Act. There is and has been no failure on the part of the Company or any of the Company’s directors

or officers, in their capacities as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act of

2002 and the rules and regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302

and 906 related to certifications.

(ll)            Disclosure Controls and Procedures. The Company has established and maintains “disclosure controls and procedures”

(as defined in Rules 13a–15(e) and 15d–15(e) of the Exchange Act); the Company’s “disclosure controls and

procedures” are reasonably designed to ensure that all information (both financial and non–financial) required to be disclosed

by the Company in the reports that it will file or furnish under the Exchange Act is recorded, processed, summarized and reported within

the time periods specified in the rules and regulations of the Commission, and that all such information is accumulated and communicated

to the Company’s management as appropriate to allow timely decisions regarding required disclosure and to make the certifications

of the Chief Executive Officer and Chief Financial Officer of the Company required under the Exchange Act with respect to such reports.

(mm)         Company’s

Accounting System. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurances that

(i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are

recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to

maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific

authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate

action is taken with respect to any differences.

(nn)

ERISA. The Company is in compliance in all material respects with all presently applicable provisions of the Employee Retirement

Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (“ERISA”);

no “reportable event” (as defined in ERISA) has occurred with respect to any “pension plan” (as defined in ERISA)

for which the Company would have any liability; the Company has not incurred and does not expect to incur liability under (i) Title

IV of ERISA with respect to termination of, or withdrawal from, any “pension plan” or (ii) Sections 412 or 4971

of the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations thereunder (the “Code”);

and each “pension plan” for which the Company would have any liability that is intended to be qualified under Section 401(a)

of the Code is so qualified in all material respects and nothing has occurred, whether by action or by failure to act, which would cause

the loss of such qualification.

(oo)

Contracts and Agreements. There are no contracts, agreements, instruments or other documents that are required to be described

in the Registration Statement, the General Disclosure Package or the Prospectus or to be filed as exhibits thereto which have not been

so described in all material respects and filed as required by Item 601(b) of Regulation S-K under the Securities Act. The copies of all

contracts, agreements, instruments and other documents (including governmental licenses, authorizations, permits, consents and approvals

and all amendments or waivers relating to any of the foregoing) that have been furnished to the Underwriter or its counsel are complete

and genuine and include all material collateral and supplemental agreements thereto. All contracts and agreements between the Company

and third parties expressly referenced in the Registration Statement, the General Disclosure Package or the Prospectus are legal, valid

and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as rights to

indemnity thereunder (as applicable) may be limited by federal or state securities laws and except as such enforceability may be limited

by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally, and subject to general principles

of equity.

(pp)

Title to Properties. Except as set forth in the Registration Statement, the General Disclosure Package and the Prospectus,

the Company has good and marketable title to all of the properties and assets reflected as owned in the financial statements referred

to in Section 6(j) above (or elsewhere in the Registration Statement, the General Disclosure Package and the Prospectus), in each

case free and clear of any security interests, mortgages, liens, encumbrances, equities, claims and other defects, except such as do not

materially and adversely affect the value of such property or assets and do not materially interfere with the use made or proposed to

be made of such property by the Company. The material real property, improvements, equipment and personal property held under lease by

the Company are held under valid and enforceable leases, with such exceptions as are not material and do not materially interfere with

the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company. The Company has

such consents, easements, rights-of-way or licenses from any person (“rights-of-way”) as are necessary to enable

the Company to conduct its business in the manner described in the Registration Statement, the General Disclosure Package and the Prospectus,

and except for such rights-of-way the lack of which would not, individually or in the aggregate, result in a Material Adverse Change.

(qq)

No Unlawful Contributions or Other Payments. No payments or inducements have been made or given, directly or indirectly,

to any federal or local official or candidate for, any federal or state office in the United States or foreign offices by the Company

or any of its officers or directors, or, to the knowledge of the Company, by any of its employees or agents or any other person in connection

with any opportunity, contract, permit, certificate, consent, order, approval, waiver or other authorization relating to the business

of the Company, except for such payments or inducements as were lawful under applicable laws, rules and regulations. Neither the Company,

nor, to the knowledge of the Company, any director, officer, agent, employee or other person associated with or acting on behalf of the

Company, (i) has used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to

political activity; (ii) made any direct or indirect unlawful payment to any government official or employee from corporate funds;

or (iii) made any bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment in connection with the business

of the Company.

(rr)

Foreign Corrupt Practices Act. None of the Company or, to the knowledge of the Company, any director, officer, agent, employee,

affiliate or other person acting on behalf of the Company, is aware of or has taken any action, directly or indirectly, that would result

in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively,

the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate

commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property,

gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined

in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the

FCPA. The Company has conducted its business in compliance with the FCPA and has instituted and maintain policies and procedures designed

to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

(ss)

Money Laundering Laws. The operations of the Company are and have been conducted at all times in compliance with applicable

financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money

laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,

issued, administered or enforced by any governmental agency (collectively, the “Money Laundering Laws”) and

no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company

with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

(tt)

OFAC. None of the Company or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or person

acting on behalf of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the

U.S. Treasury Department (“OFAC”) or the U.S. Department of State, the United Nations Security Council, the

European Union, His Majesty’s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, “Sanctions”);

and the Company will not directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such

proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person

currently subject to any U.S. sanctions administered by OFAC; nor is the Company located, organized or resident in a country or territory

that is the subject or the target of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria; and the Company

will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any

subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any

person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other

manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor,

investor or otherwise) of applicable Sanctions. For the past five years, the Company has not knowingly engaged in and are not now knowingly

engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target

of Sanctions or with any Sanctioned country.

(uu)

Exchange Listing. The Common Stock is currently listed on the Exchange under the trading symbol “ANVS”. Except

as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company has not, in the twelve (12)

months preceding the date of this Agreement, received notice from the Exchange to the effect that the Company is not in compliance with

the listing or maintenance requirements. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus,

the Company has no reason to believe that it will not in the foreseeable future continue to be in compliance with all such listing and

maintenance requirements.

(vv)

No Material Defaults. The Company has not defaulted on any installment on indebtedness for borrowed money or on any rental

on one or more long-term leases, which defaults, individually or in the aggregate, could reasonably be expected to result in a Material

Adverse Change.

(ww)

Cybersecurity. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus

or would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, the Company’s information

technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively,

“IT Systems”) are adequate for, and operate and perform as required in connection with the operation of the business

of the Company as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other

corruptants. The Company has implemented and maintained commercially reasonable physical, technical and administrative controls, policies,

procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy

and security of all IT Systems and data, including “Personal Data,” used in connection with their businesses. “Personal

Data” means (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security

number or tax identification number, driver’s license number, passport number, credit card number, bank information, or customer

or account number; (ii) any information which would qualify as “personally identifying information” under the Federal Trade

Commission Act, as amended; (iii) “personal data” as defined by GDPR; (iv) any information which would qualify as “protected

health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information

Technology for Economic and Clinical Health Act (collectively, “HIPAA”); and (v) any other piece of information that

allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an

identified person’s health or sexual orientation. Except as otherwise disclosed in the Registration Statement, the General Disclosure

Package and the Prospectus, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those

that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review

or investigations relating to the same.

(xx)

Compliance with Privacy Data. Except as otherwise disclosed in the Registration Statement, the General Disclosure Package

and the Prospectus, the Company is in material compliance with applicable state, federal and foreign data privacy and security laws and

regulations, including, to the extent applicable, the Health Insurance Portability and Accountability Act of 1996, as amended (collectively,

“HIPAA”), and the European Union General Data Protection Regulation (EU 2016/679) (collectively, the “Privacy

Laws”). To the extent required by the Privacy Laws, the Company has in place, complies in all material respects with, and takes

commercially reasonable steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating

to data privacy and security and the collection, storage, use, disclosure, and handling of Personal Data (the “Policies”).

The Company has made all disclosures to users or customers required by the Privacy Laws, and none of such disclosures made or contained

in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any Privacy Laws. Except as otherwise disclosed

in the Registration Statement and the Prospectus, the Company has not: (i) has received written notice of any actual or potential liability

under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that

would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation,

remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes

any obligation or liability by any governmental or regulatory authority under any Privacy Law.

(yy)

No Rated Securities. The Company does not have any securities rated by any “nationally recognized statistical rating

organization,” as such term is defined in Section 3(a)(62) of the Exchange Act.

Any certificate signed by

or on behalf of the Company and delivered to the Underwriter or to counsel for the Underwriter shall be deemed to be a representation

and warranty by the Company to such Underwriter as to the matters covered thereby.

PURCHASE, SALE AND DELIVERY OF OFFERED SECURITIES. On the basis of the representations, warranties and agreements herein contained,

but subject to the terms and conditions herein set forth, the Company agrees to sell to the Underwriter, and the Underwriter agrees to

purchase from the Company the number of Shares and Accompanying Warrants set forth opposite the name of the Underwriter in Schedule

A hereto.

The purchase price to be paid

by the Underwriter to the Company for the Securities will be $1.7765 per Share and Accompanying Warrant (the “Purchase Price”).

The Company will deliver (a)

the Shares to the Underwriter through the facilities of The Depository Trust Company and (b) the Accompanying Warrants in physical certificated

form at the direction of the Underwriter, issued in such names and in such denominations as the Underwriter may direct by notice in writing

to the Company given at or prior to 12:00 Noon, New York time, on the first (1st) full business day preceding the Closing Date

against payment of the aggregate Purchase Price therefor by wire transfer in federal (same day) funds to an account at a bank specified

by the Company payable to the order of the Company at the offices of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C., 919 Third

Avenue, New York, NY 10022. Time shall be of the essence, and delivery at the time and place specified pursuant to this Agreement is a

further condition of the obligations of Underwriter hereunder. The time and date of the delivery and closing shall be at 10:00 A.M., New

York time, on May 21, 2026, in accordance with Rule 15c6-1 of the Exchange Act. The time and date of such payment and delivery are herein

referred to as the “Closing Date”. The Closing Date and the location of delivery of, and the form of payment for, the

Securities may be varied by agreement among the Company and the Underwriter.

The Underwriter proposes to

offer the Securities for sale upon the terms and conditions set forth in the Prospectus.

FURTHER AGREEMENTS OF THE COMPANY. The Company agrees with the Underwriter:

(a)

Required Filings; Amendments or Supplements; Notice to the Underwriter. To prepare the Rule 462(b) Registration Statement,

if necessary, in a form approved by the Underwriter and file such Rule 462(b) Registration Statement with the Commission by 10:00 P.M.,

New York time, on the date hereof, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule

462(b) Registration Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the Rules and

Regulations; to prepare the Prospectus in a form approved by the Underwriter containing information previously omitted at the time of

effectiveness of the Registration Statement in reliance on Rule 403A, Rule 430B and Rule 430C of the Rules and Regulations and to file

such Prospectus pursuant to Rule 424(b) of the Rules and Regulations not later than the first (1st) business day following

the execution and delivery of this Agreement or, if applicable, such earlier time as may be required by the Securities Act; to notify

the Underwriter immediately of the Company’s intention to file or prepare any supplement or amendment to the Registration Statement

or to the Prospectus and to make no amendment or supplement to the Registration Statement, the General Disclosure Package or to the Prospectus

to which the Underwriter shall reasonably object by notice to the Company after a reasonable period to review; to advise the Underwriter,

promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective

or any supplement to the General Disclosure Package or the Prospectus or any amended Prospectus or any Issuer Free Writing Prospectus

has been filed and to furnish the Underwriter with copies thereof; to file promptly all material required to be filed by the Company with

the Commission pursuant to Rules 433(d) or 163(b)(2) of the Rules and Regulations, as the case may be; to file promptly all reports and

any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section 13(a), 13(c),

14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof,

the notice referred to in Rule 173(a) of the Rules and Regulations) is required in connection with the offering or sale of the Securities;

to advise the Underwriter, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order

preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus, of the suspension

of the qualification of the Securities for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for

any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement, the General Disclosure

Package or the Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing

or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such qualification,

and promptly to use its best efforts to obtain the withdrawal of such order.

(b)

[Reserved.]

(c)

Permitted Free Writing Prospectus. The Company represents and agrees that, unless it obtains the prior consent of the Underwriter,

and the Underwriter represents and agrees that, unless it obtains the prior consent of the Company, it has not made and will not make

any offer relating to the Securities that would constitute a “free writing prospectus” as defined in Rule 405 of the Rules

and Regulations (each, a “Permitted Free Writing Prospectus”); provided that the prior written consent of the Underwriter

hereto shall be deemed to have been given in respect of the Issuer Free Writing Prospectuses included in Schedule B hereto. The

Company represents that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an Issuer Free Writing

Prospectus, comply with the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Issuer Free Writing Prospectus,

including the requirements relating to timely filing with the Commission, legending and record keeping and will not take any action that

would result in the Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) of the Rules and Regulations

a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to

file thereunder.

(d)

Ongoing Compliance. If at any time prior to the date when a prospectus relating to the Securities is required to be delivered

(or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) any event occurs or condition exists as a result

of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact, or omit to state any material

fact necessary to make the statements therein, in light of the circumstances under which they were made when the Prospectus is delivered

(or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations), not misleading, or if it is necessary at any

time to amend or supplement the Registration Statement or the Prospectus or to file under the Exchange Act any document incorporated by

reference in the Prospectus to comply with the Securities Act or the Exchange Act, that the Company will promptly notify the Underwriter

thereof and upon its request will prepare an appropriate amendment or supplement or upon their request make an appropriate filing pursuant

to Section 13 or 14 of the Exchange Act in form and substance satisfactory to the Underwriter which will correct such statement or omission

or effect such compliance and will use its reasonable best efforts to have any amendment to the Registration Statement declared effective

as soon as possible. The Company will furnish without charge to the Underwriter and to any dealer in securities as many copies as the

Underwriter may from time to time reasonably request of such amendment or supplement. In case the Underwriter is required to deliver a

prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) relating to the Securities, the Company

upon the request of the Underwriter will prepare promptly an amended or supplemented Prospectus as may be necessary to permit compliance

with the requirements of Section 10(a)(3) of the Securities Act and deliver to such Underwriter as many copies as such Underwriter may

request of such amended or supplemented Prospectus complying with Section 10(a)(3) of the Securities Act.

(e)

Amendment to General Disclosure Package. If the General Disclosure Package is being used to solicit offers to buy the Securities

at a time when the Prospectus is not yet available to prospective purchasers and any event shall occur as a result of which, in the judgment

of the Company or in the reasonable opinion of the Underwriter, it becomes necessary to amend or supplement the General Disclosure Package

in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, or to make the statements

therein not conflict with the information contained or incorporated by reference in the Registration Statement then on file and not superseded

or modified, or if it is necessary at any time to amend or supplement the General Disclosure Package to comply with any law, the Company

promptly will either (i) prepare, file with the Commission (if required) and furnish to the Underwriter and any dealers an appropriate

amendment or supplement to the General Disclosure Package or (ii) prepare and file with the Commission an appropriate filing under the

Exchange Act which shall be incorporated by reference in the General Disclosure Package so that the General Disclosure Package as so amended

or supplemented will not, in the light of the circumstances then prevailing, be misleading or conflict with the Registration Statement

then on file, or so that the General Disclosure Package will comply with law.

(f)

Amendment to Issuer Free Writing Prospectus. If at any time following issuance of an Issuer Free Writing Prospectus there

occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or will conflict with the

information contained in the Registration Statement, Pricing Prospectus or Prospectus, including any document incorporated by reference

therein and any prospectus supplement deemed to be a part thereof and not superseded or modified or included or would include an untrue

statement of a material fact or omitted or would omit to state a material fact required to be stated therein or necessary in order to

make the statements therein, in the light of the circumstances prevailing at the subsequent time, not misleading, the Company has promptly

notified or will promptly notify the Underwriter so that any use of the Issuer Free Writing Prospectus may cease until it is amended or

supplemented and has promptly amended or will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to

eliminate or correct such conflict, untrue statement or omission. The foregoing sentence does not apply to statements in or omissions

from any Issuer Free Writing Prospectus in reliance upon, and in conformity with, written information furnished to the Company through

the Underwriter specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriter’s Information.

(g)

Delivery of Registration Statement. To the extent not available on the Commission’s Electronic Data Gathering, Analysis

and Retrieval system or any successor system (“EDGAR”), upon the request of the Underwriter, to furnish promptly to

the Underwriter and to counsel for the Underwriter a signed copy of the Registration Statement as originally filed with the Commission,

and of each amendment thereto filed with the Commission, including all consents and exhibits filed therewith.

(h)

Delivery of Copies. Upon request of the Underwriter, to the extent not available on EDGAR, to deliver promptly to the Underwriter

in New York City such number of the following documents as the Underwriter shall reasonably request: (i) conformed copies of the Registration

Statement as originally filed with the Commission (in each case excluding exhibits), (ii) each Preliminary Prospectus, (iii) any Issuer

Free Writing Prospectus, (iv) the Prospectus (the delivery of the documents referred to in clauses (i), (ii), (iii) and (iv) of this paragraph

(h) to be made not later than 10:00 A.M., New York time, on the business day following the execution and delivery of this Agreement),

(v) conformed copies of any amendment to the Registration Statement (excluding exhibits), (vi) any amendment or supplement to the General

Disclosure Package or the Prospectus (the delivery of the documents referred to in clauses (v) and (vi) of this paragraph (h) to be made

not later than 10:00 A.M., New York City time, on the business day following the date of such amendment or supplement) and (vii) any document

incorporated by reference in the General Disclosure Package or the Prospectus (excluding exhibits thereto) (the delivery of the documents

referred to in clause (vi) of this paragraph (h) to be made not later than 10:00 A.M., New York City time, on the business day following

the date of such document).

(i)

Blue Sky Compliance. To take promptly from time to time such actions as the Underwriter may reasonably request to qualify

the Securities for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Underwriter

may reasonably designate and to continue such qualifications in effect, and to comply with such laws, for so long as required to permit

the offer and sale of Securities in such jurisdictions; provided that the Company shall not be obligated to (i) qualify as a foreign corporation

in any jurisdiction in which it is not so qualified, (ii) file a general consent to service of process in any jurisdiction or (iii) subject

itself to taxation in any such jurisdiction if it is not otherwise so subject.

(j)

Reports. Upon request, during the period of five (5) years from the date hereof, to deliver to the Underwriter, (i) as soon

as they are available, copies of all reports or other communications (financial or other) furnished to stockholders, and (ii) as soon

as they are available, copies of any reports and financial statements furnished or filed with the Commission or any national securities

exchange on which the Common Stock is listed. However, so long as the Company is subject to the reporting requirements of either Section

13 or Section 15(d) of the Exchange Act and is timely filing reports with the Commission on EDGAR, it is not required to furnish such

reports or statements to the Underwriter.

(k)

Lock-Up. During the period commencing on and including the date hereof and ending on and including the ninetieth (90th)

day following the date of this Agreement (the “Lock-Up Period”), the Company will not, without the prior written consent

of the Underwriter (which consent may be withheld at the sole discretion of the Underwriter), directly or indirectly offer, sell (including,

without limitation, any short sale), assign, transfer, pledge, contract to sell, establish an open “put equivalent position”

within the meaning of Rule 16a-1(h) under the Exchange Act, or otherwise dispose of, or announce the offering of, or file any registration

statement under the Securities Act in respect of, any Common Stock, options, rights or warrants to acquire Common Stock or securities

exchangeable or exercisable for or convertible into Common Stock (other than is contemplated by this Agreement with respect to the Securities)

or publicly announce any intention to do any of the foregoing; provided, however, that the Company may (i) issue Common Stock, options

to purchase Common Stock, restricted stock units, and other equity awards, shares of Common Stock underlying options, restricted stock

units and other equity awards granted and other securities, each pursuant to any director or employee stock incentive plan, other equity

incentive plan, stock ownership plan or dividend reinvestment plan of the Company in effect on the date hereof and described in the General

Disclosure Package; (ii) issue Common Stock pursuant to the conversion of securities or the exercise of warrants, which securities or

warrants are outstanding on the date hereof and described in the General Disclosure Package, as well as the Warrant Shares upon exercise

of Accompanying Warrants; (iii) adopt a new equity incentive plan, amend any existing equity incentive plan (including without limitation,

to increase the number of shares reserved for issuance thereunder) and file a registration statement on Form S-8 under the Securities

Act to register the offer and sale of securities to be issued pursuant to such new equity incentive plan or amended equity incentive plan,

and issue securities pursuant to such new equity incentive plan or amended equity incentive plan (including, without limitation, the issuance

of shares of Common Stock upon the exercise of options or other securities issued pursuant to such new equity incentive plan or amended

equity incentive plan), provided that (1) such new equity incentive plan or amended equity incentive plan satisfies the transaction requirements

of General Instruction A.1 of Form S-8 under the Securities Act and (2) this clause (iii) shall not be available unless each recipient

of shares of Common Stock, or securities exchangeable or exercisable for or convertible into Common Stock, (A) pursuant to such new equity

incentive plan or (B) representing the additional shares reserved for issuance under such existing equity incentive plan pursuant to such

amendment to such existing equity incentive plan, shall be contractually prohibited from selling, offering, disposing of or otherwise

transferring any such shares or securities during the remainder of the Lock-Up Period; (iv) enter into an agreement providing for the

issuance of Common Stock or securities convertible into or exercisable for shares of Common Stock in connection with any acquisition,

joint venture, collaboration, licensing, commercial relationship or other strategic transaction or any debt financing transaction, and

the issuance of any such securities pursuant to any such agreement, provided that the aggregate number of shares of Common Stock, or any

securities convertible into or exercisable or exchangeable for Common Stock, that the Company may issue or agree to issue pursuant to

this clause (iv) shall not exceed 5% of the total outstanding shares of Common Stock immediately following the issuance of the Securities

pursuant hereto; and (vi) issue shares of Common Stock pursuant to the Equity Distribution Agreement, dated December 11, 2024, between

the Company and Oppenheimer & Co. Inc., as sales agent, or any replacement “at the market” offering program (the “ATM”),

provided that the Lock-Up Period applicable to this clause (vi) shall commence on and include the date hereof and end on and include the

sixtieth (60th) day following the date of this Agreement, and provided further, that for the remainder of the Lock-Up Period, the Company

shall only sell shares of Common Stock or issue a sales notice pursuant to the ATM if the price per share of Common Stock is above $2.50.

The Company will cause all executive officers and directors of the Company listed on Schedule E attached hereto to furnish to the

Underwriter, prior to the Closing Date, the “lock-up” agreement substantially in the form of Exhibit I hereto.

(l)

Delivery of SEC Correspondence. To supply the Underwriter with copies of all correspondence to and from, and all documents

issued to and by, the Commission in connection with the registration of the Securities under the Securities Act or any of the Registration

Statement, any Preliminary Prospectus or the Prospectus, or any amendment or supplement thereto or document incorporated by reference

therein.

(m)

Press Releases. Prior to the Closing Date, not to issue any press release or other communication directly or indirectly

or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business

prospects (except for routine oral marketing communications in the ordinary course of business and consistent with the past practices

of the Company and of which the Underwriter is notified), without the prior consent of the Underwriter, unless in the judgment of the

Company and its counsel, and after notification to the Underwriter, such press release or communication is required by law.

(n)

Compliance with Regulation M. Until the Underwriter shall have notified the Company of the completion of the resale of the

Securities, that the Company will not, and will use its reasonable best efforts to cause its affiliated purchasers (as defined in Regulation

M under the Exchange Act) not to, either alone or with one or more other persons, bid for or purchase, for any account in which it or

any of its affiliated purchasers has a beneficial interest, any Securities, or attempt to induce any person to purchase any Securities;

and not to, and to use its reasonable best efforts to cause its affiliated purchasers not to, make bids or purchase for the purpose of

creating actual, or apparent, active trading in or of raising the price of the Securities.

(o)

Registrar, Transfer Agent and Warrant Agent. To maintain, at its expense, a registrar and transfer agent for the Shares

and a warrant agent for the Accompanying Warrants.

(p)

Use of Proceeds. To apply the net proceeds from the sale of the Securities as set forth in the Registration Statement, the

General Disclosure Package and the Prospectus under the heading “Use of Proceeds,” and except as disclosed in the General

Disclosure Package, the Company does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding

debt owed to any affiliate of the Underwriter.

(q)

Exchange Listing. To use its reasonable best efforts to list for quotation the Shares and the Warrant Shares on the Exchange.

(r)

Performance of Covenants and Satisfaction of Conditions. To use its reasonable best efforts to do and perform all things

required to be done or performed under this Agreement by the Company prior to the Closing Date and to satisfy all conditions precedent

to the delivery of the Securities.

(s)

License to use Marks. Upon request of the Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic

version of the Company’s trademarks, service marks and corporate logo for use on the website, if any, operated by such Underwriter

for the purpose of facilitating the on-line offering of the Securities (the “License”); provided, however, that the

License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred.

(t)

Share Reserve. The Company will reserve and keep available at all times a sufficient number of shares of Common Stock for

the purpose of enabling the Company to issue the Warrant Shares.

(u)

Registration Statement for the Accompanying Warrants. The Company will, at all times while any of the Accompanying Warrants

are outstanding and exercisable, use its commercially reasonable efforts to maintain a registration statement covering the issue and sale

of the Warrant Shares upon exercise of the Accompanying Warrants such that the Warrant Shares, when issued, will not be subject to resale

restrictions under the Securities Act except to the extent that the Warrant Shares are owned by affiliates.

PAYMENT OF EXPENSES. The Company agrees to pay, or reimburse if paid by the Underwriter, whether or not the transactions contemplated

hereby are consummated or this Agreement is terminated: (a) the costs incident to the authorization, issuance, sale, preparation and delivery

of the Securities and any taxes payable in that connection; (b) the costs incident to the registration of the Securities under the Securities

Act; (c) the costs incident to the preparation, printing and distribution of the Registration Statement, the Base Prospectus, any Preliminary

Prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the Prospectus, any amendments, supplements and exhibits

thereto or any document incorporated by reference therein and the costs of printing, reproducing and distributing this Agreement, the

Accompanying Warrants and any closing documents by mail, telex or other means of communications; (d) the fees and expenses (including,

subject to clause (j), related fees and expenses of counsel for the Underwriter) incurred in connection with securing any required review

by FINRA of the terms of the sale of the Securities and any filings made with FINRA; (e) any applicable listing or other fees; (f) the

fees and expenses (including, subject to clause (j), related fees and expenses of counsel to the Underwriter) of qualifying the Securities

under the securities laws of the several jurisdictions as provided in Section 4(i) and of preparing, printing and distributing wrappers,

Blue Sky Memoranda and Legal Investment Surveys; (g) the cost of preparing and printing stock certificates; (h) all fees and expenses

of the registrar, transfer agent and warrant agent of the Shares and Accompanying Warrants, as applicable; (i) the expenses of the Company

relating to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities,

including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated

with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations

with the prior approval of the Company, travel and lodging expenses of the officers of the Company and such consultants; (j) the fees

and expenses of counsel to the Underwriter in an amount not to exceed an aggregate of $75,000 (inclusive of amounts reimbursed pursuant

to clauses (d) and (f) of this Section 5); and (k) all other costs and expenses incurred by the Company incident to the offering of the

Securities or the performance of the obligations of the Company under this Agreement (including, without limitation, the fees and expenses

of the Company’s counsel and the Company’s independent accountants); provided that, except to the extent otherwise provided

in this Section 5 and in Section 9, the Underwriter shall pay its own costs and expenses, including the fees and expenses of its counsel

not contemplated herein, any transfer taxes on the resale of any Securities by it and the expenses of advertising any offering of the

Securities made by the Underwriter.

CONDITIONS OF UNDERWRITER’S OBLIGATIONS. The obligations of the Underwriter hereunder are subject to the accuracy, when made

and as of the Applicable Time and on the Closing Date, of the representations and warranties of the Company contained herein, to the accuracy

of the statements of the Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its

obligations hereunder, and to each of the following additional terms and conditions:

(a)

Registration Compliance; No Stop Orders. The Registration Statement has become effective under the Securities Act, and no

stop order suspending the effectiveness of the Registration Statement or any part thereof, preventing or suspending the use of any Base

Prospectus, any Preliminary Prospectus, the Prospectus or any Permitted Free Writing Prospectus or any part thereof shall have been issued

and no proceedings for that purpose or pursuant to Section 8A under the Securities Act shall have been initiated or threatened by the

Commission, and all requests for additional information on the part of the Commission (to be included or incorporated by reference in

the Registration Statement or the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Underwriter;

the Rule 462(b) Registration Statement, if any, each Issuer Free Writing Prospectus and the Prospectus shall have been filed with the

Commission within the applicable time period prescribed for such filing by, and in compliance with, the Rules and Regulations and in accordance

with Section 4(a), and the Rule 462(b) Registration Statement, if any, shall have become effective immediately upon its filing with the

Commission; and FINRA shall have raised no unresolved objection to the fairness and reasonableness of the terms of this Agreement or the

transactions contemplated hereby.

(b)

No Material Misstatements. The Underwriter shall not have discovered and disclosed to the Company on or prior to the Closing

Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the opinion

of counsel for the Underwriter, is material or omits to state any fact which, in the opinion of such counsel, is material and is required

to be stated therein or is necessary to make the statements therein not misleading, or that the General Disclosure Package, any Issuer

Free Writing Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement of fact which, in the opinion

of such counsel, is material or omits to state any fact which, in the opinion of such counsel, is material and is necessary in order to

make the statements, in the light of the circumstances in which they were made, not misleading.

(c)

Corporate Proceedings. All corporate proceedings incident to the authorization, form and validity of each of this Agreement,

the Securities, the Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus and the Prospectus and

the transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Underwriter, and the

Company shall have furnished to such counsel all documents and information that they may reasonably request to enable them to pass upon

such matters.

(d)

Opinion and 10b-5 Statement of Counsel for the Company. Loeb & Loeb LLP shall have furnished to the Underwriter such

counsel’s written opinion and negative assurance statement, as counsel to the Company, addressed to the Underwriter and dated the

Closing Date, in form and substance reasonably satisfactory to the Underwriter.

(e)

Opinion of Intellectual Property Counsel for the Company. Each of (i) Duane Morris LLP and (ii) Davidson Kappel LLC, intellectual

property counsels to the Company, shall have furnished to the Underwriter such counsel’s written opinion, as intellectual property

counsel to the Company, addressed to the Underwriter and dated the Closing Date, in form and substance reasonably satisfactory to the

Underwriter.

(f)

Opinion and 10b-5 Statement of Counsel for the Underwriter. The Underwriter shall have received from Mintz, Levin, Cohn,

Ferris, Glovsky and Popeo, P.C., counsel for the Underwriter, such opinion or opinions and negative assurance statement, dated the Closing

Date, with respect to such matters as the Underwriter may reasonably require, and the Company shall have furnished to such counsel such

documents as they request for enabling them to pass upon such matters.

(g)

Comfort Letters. At the time of the execution of this Agreement, the Underwriter shall have received from Ernst & Young

LLP, which served and serves as the independent registered public accounting firm for the Company, a letter addressed to the Underwriter,

executed and dated such date, in form and substance reasonably satisfactory to the Underwriter (i) confirming that they are an independent

registered accounting firm with respect to the Company within the meaning of the Securities Act and the Rules and Regulations and PCAOB

and (ii) stating the conclusions and findings of such firm, of the type ordinarily included in accountants’ “comfort letters”

to underwriters for offerings similar to that contemplated by this Agreement, with respect to the financial statements and certain financial

information contained or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus.

(h)

Bring Down Comfort. On the effective date of any post-effective amendment to the Registration Statement and on the Closing

Date, the Underwriter shall have received a letter (a “bring-down letter”) from Ernst & Young LLP addressed to

the Underwriter and dated the Closing Date confirming, as of the date of such bring-down letter (or, with respect to matters involving

changes or developments since the respective dates as of which specified financial information is given in the General Disclosure Package

and the Prospectus, as the case may be, as of a date not more than two (2) business days prior to the date of such bring-down letter),

the conclusions and findings of such firm, of the type ordinarily included in accountants’ “comfort letters” to underwriters

for offerings similar to that contemplated by this Agreement, with respect to the financial information and other matters covered by such

letter delivered to the Underwriter concurrently with the execution of this Agreement pursuant to paragraph (g) of this Section 6.

(i)

Officer’s Certificate. The Company shall have furnished to the Underwriter a certificate, dated the Closing Date,

of its President and Chief Executive Officer stating in such Officer’s capacity as an officer of the Company on behalf of the Company

that (i) no stop order suspending the effectiveness of the Registration Statement (including, for avoidance of doubt, any Rule 462(b)

Registration Statement), or any post-effective amendment thereto, shall be in effect and no proceedings for such purpose shall have been

instituted or, to their knowledge, threatened by the Commission, (ii) for the period from and including the date of this Agreement through

and including the Closing Date, there has not occurred any Material Adverse Change, (iii) to her knowledge, after reasonable investigation,

as of the Closing Date, the representations and warranties of the Company in this Agreement are true and correct and the Company has complied

with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date, and

(iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference

in the General Disclosure Package, any Material Adverse Change in the financial position or results of operations of the Company, or any

change or development that, singularly or in the aggregate, would reasonably be expected to have a Material Adverse Change, except as

set forth in the General Disclosure Package and the Prospectus.

(j)

No Material Adverse Change. Since the date of the latest audited financial statements included in the General Disclosure

Package or incorporated by reference in the General Disclosure Package as of the date hereof, (i) the Company shall not have sustained

any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from

any labor dispute or court or governmental action, order or decree, otherwise than as set forth in the General Disclosure Package, and

(ii) there shall not have been any change in the capital stock (other than upon the exercise of any stock option or vesting of any equity

award, in each case, outstanding as of the date hereof, the grant of any stock option or other stock award under existing equity plans

or the exercise of any warrants outstanding as of the date hereof, in each case, as set forth in the General Disclosure Package) or increase

in the long-term debt of the Company, or any change, or any development involving a prospective change, in or affecting the business,

general affairs, management, financial position, stockholders’ equity or results of operations of the Company, otherwise than as

set forth in the General Disclosure Package, the effect of which, in any such case described in clause (i) or (ii) of this paragraph (j),

is, in the judgment of the Underwriter, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or

delivery of the Securities on the terms and in the manner contemplated in the General Disclosure Package.

(k)

No Legal Impediment to Issuance. No action shall have been taken and no law, statute, rule, regulation or order shall have

been enacted, adopted or issued by any governmental or regulatory agency or body which would prevent the issuance or sale of the Securities;

and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been

issued which would prevent the issuance or sale of the Securities or materially and adversely affect or potentially materially and adversely

affect the business or operations of the Company.

(l)

[Reserved].

(m)

Market Conditions. Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the following:

(i) trading in any of the Company’s securities shall have been suspended or materially limited by the Commission or the Exchange,

or trading in securities generally on the New York Stock Exchange, Nasdaq Global Select Market, Nasdaq Global Market, Nasdaq Capital Market

or the NYSE American LLC or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter

market, shall have been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been established

on any such exchange or such market by the Commission, by such exchange or market or by any other regulatory body or governmental authority

having jurisdiction, (ii) a banking moratorium shall have been declared by Federal or state authorities or a material disruption has occurred

in commercial banking or securities settlement or clearance services in the United States, (iii) the United States shall have become engaged

in hostilities, or the subject of an act of terrorism, or there shall have been an outbreak of or escalation in hostilities involving

the United States, or there shall have been a declaration of a national emergency or war by the United States or (iv) there shall have

occurred such a material adverse change in general economic, political or financial conditions (or the effect of international conditions

on the financial markets in the United States shall be such) as to make it, in the judgment of the Underwriter, impracticable or inadvisable

to proceed with the sale or delivery of the Securities on the terms and in the manner contemplated in the General Disclosure Package and

the Prospectus.

(n)

Exchange Listing. The Company shall have submitted a Supplemental Listing Application with the Exchange and shall have received

approval thereto from the Exchange.

(o)

Good Standing. The Underwriter shall have received on and as of the Closing Date satisfactory evidence of the good standing

of the Company in its jurisdiction of organization and its good standing as a foreign entity in such other jurisdictions as the Underwriter

may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate Governmental Authorities

of such jurisdictions.

(p)

Lock-Up Agreements. The Underwriter shall have received the written agreements, substantially in the form of Exhibit

I hereto, of all executive officers and directors of the Company listed on Schedule E attached hereto.

(q)

Secretary’s Certificate. The Company shall have furnished to the Underwriter a Secretary’s Certificate of the

Company, in form and substance reasonably satisfactory to counsel for the Underwriter and customary for the type of offering contemplated

by this Agreement.

(r)

Acting Chief Financial Officer’s Certificate. The Company shall have furnished to the Underwriter an Acting Chief

Financial Officer’s Certificate of the Company, as needed, in form and substance reasonably satisfactory to counsel for the Underwriter

and customary for the type of offering contemplated by this Agreement, with respect to certain financial information of the Company included

in the General Disclosure Package and the Prospectus.

(s)

Accompanying Warrants. The Underwriter shall have received copies, duly executed by the Company, of the Accompanying Warrants.

There shall exist no event or condition which would constitute a default or an event of default under the Accompanying Warrants.

(t)

Additional Documents. On or prior to the Closing Date, the Company shall have furnished to the Underwriter such further

customary certificates and documents as the Underwriter may reasonably request.

All opinions, letters, evidence

and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if

they are in form and substance reasonably satisfactory to counsel for the Underwriter.

INDEMNIFICATION AND CONTRIBUTION.

(a)

Indemnification of Underwriter by the Company. The Company shall indemnify and hold harmless the Underwriter, its affiliates,

directors, officers, managers, members, employees, representatives and agents and each person, if any, who controls the Underwriter within

the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the “Underwriter Indemnified

Parties,” and each an “Underwriter Indemnified Party”) against any loss, claim, damage, expense or liability

whatsoever (or any action, investigation or proceeding in respect thereof), joint or several, to which such Underwriter Indemnified Party

may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation

or proceeding arises out of or is based upon (A) any untrue statement or alleged untrue statement of a material fact contained in any

Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant

to Rule 433(d) of the Rules and Regulations, the Registration Statement, the Prospectus, or in any amendment or supplement thereto or

document incorporated by reference therein or in any materials or information provided to investors by, or with the approval of, the Company

in connection with the marketing of the offering of the Securities, including any roadshow or investor presentations made to investors

by the Company (whether in person or electronically) (“Marketing Materials”) or (B) the omission or alleged omission

to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to

be filed pursuant to Rule 433(d) of the Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement

thereto or document incorporated by reference therein or in any Marketing Materials, a material fact required to be stated therein or

necessary to make the statements therein not misleading, and shall reimburse each Underwriter Indemnified Party promptly upon demand for

any legal fees or other expenses reasonably incurred by that Underwriter Indemnified Party in connection with investigating, or preparing

to defend, or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such

loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses are incurred; provided, however,

that the Company shall not be liable in any such case to the extent that any such loss, claim, damage, expense or liability arises out

of or is based upon an untrue statement or alleged untrue statement in, or omission or alleged omission from any Preliminary Prospectus,

the Registration Statement or the Prospectus, or any such amendment or supplement thereto, any Issuer Free Writing Prospectus or any Marketing

Materials made in reliance upon and in conformity with written information furnished to the Company through the Underwriter specifically

for use therein, which information the parties hereto agree is limited to the Underwriter’s Information.

The indemnity agreement in

this Section 7(a) is not exclusive and is in addition to each other liability which the Company might have under this Agreement or otherwise,

and shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to any Underwriter

Indemnified Party.

(b)

Indemnification of Company by the Underwriter. The Underwriter shall indemnify and hold harmless the Company and its directors,

its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15

of the Securities Act or Section 20 of the Exchange Act (collectively the “Company Indemnified Parties” and each a

“Company Indemnified Party”) against any loss, claim, damage, expense or liability whatsoever (or any action, investigation

or proceeding in respect thereof), joint or several, to which such Company Indemnified Party may become subject, under the Securities

Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises out of or is based

upon (i) any untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus, any Issuer Free

Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations,

the Registration Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein,

or (ii) the omission or alleged omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer

information” filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, the Registration Statement or the

Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, a material fact required to be stated

therein or necessary to make the statements therein not misleading, but in each case only to the extent that the untrue statement or alleged

untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the

Company through the Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriter’s

Information, and shall reimburse the Company Indemnified Parties for any legal or other expenses reasonably incurred by such party in

connection with investigating or preparing to defend or defending against or appearing as third party witness in connection with any such

loss, claim, damage, liability, action, investigation or proceeding, as such fees and expenses are incurred. This indemnity agreement

is not exclusive and will be in addition to any liability which the Underwriter might otherwise have and shall not limit any rights or

remedies which may otherwise be available under this Agreement, at law or in equity to the Company Indemnified Parties.

(c)

Promptly after receipt by an indemnified party under this Section 7 of notice of the commencement of any action, the indemnified

party shall, if a claim in respect thereof is to be made against an indemnifying party under this Section 7, notify such indemnifying

party in writing of the commencement of that action; provided, however, that the failure to notify the indemnifying party shall not relieve

it from any liability which it may have under this Section 7 except to the extent it has been materially prejudiced by such failure; and,

provided, further; that the failure to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified

party otherwise than under this Section 7. If any such action shall be brought against an indemnified party, and it shall notify the indemnifying

party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other

similarly notified indemnifying party, to assume the defense of such action with counsel reasonably satisfactory to the indemnified party

(which counsel shall not, except with the written consent of the indemnified party, be counsel to the indemnifying party). After notice

from the indemnifying party to the indemnified party of its election to assume the defense of such action, except as provided herein,

the indemnifying party shall not be liable to the indemnified party under Section 7 for any legal or other expenses subsequently incurred

by the indemnified party in connection with the defense of such action other than reasonable costs of investigation; provided, however;

that any indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense of such

action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified

party unless (i) the employment thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification

under Section 7(a) or the Underwriter in the case of a claim for indemnification under Section 7(b), (ii) such indemnified party shall

have been advised by its counsel that there may be one or more legal defenses available to it which are different from or additional to

those available to the indemnifying party, or (iii) the indemnifying party has failed to assume the defense of such action and employ

counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice of the commencement of the action

or the indemnifying party does not diligently defend the action after assumption of the defense, in which case, if such indemnified party

notifies the indemnifying party in writing that it elects to employ separate counsel at the expense of the indemnifying party, the indemnifying

party shall not have the right to assume the defense of (or, in the case of a failure to diligently defend the action after assumption

of the defense, to continue to defend) such action on behalf of such indemnified party and the indemnifying party shall be responsible

for legal or other expenses subsequently incurred by such indemnified party in connection with the defense of such action; provided, however,

that the indemnifying party shall not, in connection with any one such action or separate but substantially similar or related actions

in the same jurisdiction arising out of the same general allegations or circumstances, be liable for the reasonable fees and expenses

of more than one separate firm of attorneys at any time for all such indemnified parties (in addition to any local counsel), which firm

shall be designated in writing by the Underwriter if the indemnified parties under this Section 7 consist of any Underwriter Indemnified

Party or by the Company if the indemnified parties under this Section 7 consist of any Company Indemnified Parties. Subject to this Section

7(c), the amount payable by an indemnifying party under Section 7 shall include, but not be limited to, (x) reasonable legal fees and

expenses of counsel to the indemnified party and any other expenses in investigating, or preparing to defend or defending against, or

appearing as a third party witness in respect of, or otherwise incurred in connection with, any action, investigation, proceeding or claim,

and (y) all amounts paid in settlement of any of the foregoing. No indemnifying party shall, without the prior written consent of the

indemnified parties, settle or compromise or consent to the entry of judgment with respect to any pending or threatened action or any

claim whatsoever, in respect of which indemnification or contribution could be sought under this Section 7 (whether or not the indemnified

parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release

of each indemnified party in form and substance reasonably satisfactory to such indemnified party from all liability arising out of such

action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf

of any indemnified party. Subject to the provisions of the following sentence, no indemnifying party shall be liable for settlement of

any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably

withheld or delayed), but if settled with its written consent, if its consent has been unreasonably withheld or delayed or if there be

a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold harmless any indemnified party from

and against any loss or liability by reason of such settlement or judgment. In addition, if at any time an indemnified party shall have

requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel, such indemnifying party agrees

that it shall be liable for any settlement of the nature contemplated by Sections 7(a) or 7(b) effected without its written consent if

(i) such settlement is entered into more than forty-five (45) days after receipt by such indemnifying party of the request for reimbursement,

(ii) such indemnifying party shall have received notice of the terms of such settlement at least thirty (30) days prior to such settlement

being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request

prior to the date of such settlement.

(d)

If the indemnification provided for in this Section 7 is unavailable or insufficient to hold harmless an indemnified party under

Section 7(a) or 7(b), then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid,

payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense or liability (or any action,

investigation or proceeding in respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect the relative benefits

received by the Company on the one hand and the Underwriter on the other from the offering of the Securities, or (ii) if the allocation

provided by clause (i) of this Section 7(d) is not permitted by applicable law, in such proportion as is appropriate to reflect not only

the relative benefits referred to in clause (i) of this Section 7(d) but also the relative fault of the Company on the one hand and the

Underwriter on the other with respect to the statements, omissions, acts or failures to act which resulted in such loss, claim, damage,

expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant equitable considerations.

The relative benefits received by the Company on the one hand and the Underwriter on the other with respect to such offering shall be

deemed to be in the same proportion as the total net proceeds from the offering of the Securities purchased under this Agreement (before

deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriter with

respect to the Securities purchased under this Agreement, in each case as set forth in the table on the cover page of the Prospectus.

The relative fault of the Company on the one hand and the Underwriter on the other shall be determined by reference to, among other things,

whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates

to information supplied by the Company on the one hand or the Underwriter on the other, the intent of the parties and their relative knowledge,

access to information and opportunity to correct or prevent such untrue statement, omission, act or failure to act; provided that the

parties hereto agree that the written information furnished to the Company through the Underwriter for use in the Preliminary Prospectus,

the Registration Statement or the Prospectus, or in any amendment or supplement thereto, consists solely of the Underwriter’s Information.

(e)

The Company and the Underwriter agree that it would not be just and equitable if contributions pursuant to Section 7(d) above were

to be determined by pro rata allocation or by any other method of allocation which does not take into account the equitable considerations

referred to Section 7(d) above. The amount paid or payable by an indemnified party as a result of the loss, claim, damage, expense, liability,

action, investigation or proceeding referred to in Section 7(d) above shall be deemed to include, subject to the limitations set forth

above, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating, preparing to defend

or defending against or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such loss, claim,

damage, expense, liability, action, investigation or proceeding. Notwithstanding the provisions of this Section 7, the Underwriter shall

not be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by

such Underwriter with respect to the offering of the Securities exceeds the amount of any damages which the Underwriter has otherwise

paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission, act or alleged act or

failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(t) of the

Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

TERMINATION. The obligations of the Underwriter hereunder may be terminated by the Underwriter, in its absolute discretion by notice

given to the Company prior to delivery of and payment for the Securities if, prior to that time, any of the events described in Sections

6(j) or 6(m) have occurred or if the Underwriter shall decline to purchase the Securities for any reason permitted under this Agreement.

REIMBURSEMENT OF UNDERWRITER’S EXPENSES. Notwithstanding anything to the contrary in this Agreement, if (a) this Agreement

shall have been terminated pursuant to Section 8, (b) the Company shall fail to tender the Securities for delivery to the Underwriter

for any reason not permitted under this Agreement, (c) the Underwriter shall decline to purchase the Securities for any reason permitted

under this Agreement or (d) the sale of the Securities is not consummated because any condition to the obligations of the Underwriter

set forth herein is not satisfied or because of the refusal, inability or failure on the part of the Company to perform any agreement

herein or to satisfy any condition or to comply with the provisions hereof, then in addition to the payment of amounts in accordance with

Section 5, the Company shall, pro rata based on the number of Securities it agreed to sell hereunder, reimburse the Underwriter for the

reasonable and documented fees and expenses of Underwriter’s counsel and for such other reasonable and documented out-of-pocket

expenses as shall have been reasonably incurred by them in connection with this Agreement and the proposed purchase of the Securities,

including, without limitation, reasonable travel and lodging expenses of the Underwriter, and upon demand the Company shall pay the full

amount thereof to the Underwriter not to exceed $25,000 in the aggregate.

10.

[RESERVED].

11.

ABSENCE OF FIDUCIARY RELATIONSHIP. The Company acknowledges and agrees that:

(a)

the Underwriter’s responsibility to the Company is solely contractual in nature, the Underwriter has been retained solely

to act as underwriter in connection with the sale of the Securities and no fiduciary, advisory or agency relationship between the Company

and the Underwriter have been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the

Underwriter has advised or is advising the Company on other matters;

(b)

the price of the Shares and Accompanying Warrants set forth in this Agreement was established by the Company following discussions

and arms-length negotiations with the Underwriter, and the Company is capable of evaluating and understanding, and understands and accepts,

the terms, risks and conditions of the transactions contemplated by this Agreement;

(c)

it has been advised that the Underwriter and its affiliates are engaged in a broad range of transactions which may involve interests

that differ from those of the Company and that the Underwriter has no obligation to disclose such interests and transactions to the Company

by virtue of any fiduciary, advisory or agency relationship; and

(d)

it waives, to the fullest extent permitted by law, any claims it may have against the Underwriter for breach of fiduciary duty

or alleged breach of fiduciary duty and agrees that the Underwriter shall have no liability (whether direct or indirect) to the Company

in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including

stockholders, employees or creditors of the Company.

12.

SUCCESSORS; PERSONS ENTITLED TO BENEFIT OF AGREEMENT. This Agreement shall inure to the benefit of and be binding upon the Underwriter,

the Company and their respective successors and assigns. Nothing expressed or mentioned in this Agreement is intended or shall be construed

to give any person, other than the persons mentioned in the preceding sentence, any legal or equitable right, remedy or claim under or

in respect of this Agreement, or any provisions herein contained, this Agreement and all conditions and provisions hereof being intended

to be and being for the sole and exclusive benefit of such persons and for the benefit of no other person; except that the representations,

warranties, covenants, agreements and indemnities of the Company contained in this Agreement shall also be for the benefit of the Underwriter

Indemnified Parties, and the indemnities of the Underwriter shall be for the benefit of the Company Indemnified Parties. It is understood

that the Underwriter’s responsibility to the Company is solely contractual in nature and the Underwriter does not owe the Company,

or any other party, any fiduciary duty as a result of this Agreement. No purchaser of any of the Securities from the Underwriter shall

be deemed to be a successor or assign by reason merely of such purchase.

13.

SURVIVAL OF INDEMNITIES, REPRESENTATIONS, WARRANTIES, ETC. The respective indemnities, covenants, agreements, representations,

warranties and other statements of the Company and the Underwriter, as set forth in this Agreement or made by them respectively, pursuant

to this Agreement, shall remain in full force and effect, regardless of any investigation made by or on behalf of the Underwriter, the

Company or any person controlling any of them and shall survive delivery of and payment for the Securities. Notwithstanding any termination

of this Agreement, including without limitation any termination pursuant to Section 8, the indemnities, covenants, agreements, representations,

warranties and other statements forth in Sections 2, 5, 7 and 9 and Sections 11 through 21, inclusive, of this Agreement shall not terminate

and shall remain in full force and effect at all times.

14.

RECOGNITION OF THE U.S. SPECIAL RESOLUTION REGIMES.

(a)

In the event that the Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,

the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to

the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and

obligation, were governed by the laws of the United States or a state of the United States.

(b)

In the event that the Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding

under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted

to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement

were governed by the laws of the United States or a state of the United States.

15.

NOTICES. All statements, requests, notices and agreements hereunder shall be in writing, and:

(a)

if to the Underwriter, shall be delivered or sent by mail to Canaccord Genuity LLC, Penn 1, One Pennsylvania Plaza, Suite 2900,

New York, NY 10119, Attention: General Counsel, with a copy to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., 919 Third Avenue,

New York, NY 10022, Attention: Ivan Blumenthal; and

(b)

if to the Company, shall be delivered or sent by mail, telex, facsimile transmission or email to Annovis Bio, Inc., 101 Lindenwood

Drive, Suite 225, Malvern, PA 19355, Attention: Chief Executive Officer, with a copy to Loeb & Loeb LLP, 345 Park Avenue, New York,

NY 10154, Attention: Joan Guilfoyle.

16.

DEFINITION OF CERTAIN TERMS. For purposes of this Agreement, (a) “affiliate” has the meaning set forth in Rule

405 under the Securities Act, (b) “business day” means any day on which the Exchange is open for trading and (c) “subsidiary”

has the meaning set forth in Rule 405 of the Rules and Regulations; (d) “BHC Act Affiliate” has the meaning assigned

to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k), (e) “Covered Entity”

means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R.

§ 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b);

or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b), (f) “Default

Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81,

47.2 or 382.1, as applicable, (g) “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance

Act and the regulations promulgated thereunder and (ii) Title H of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the

regulations promulgated thereunder.

17.

GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including

without limitation Section 5-1401 of the New York General Obligations. The Company irrevocably (a) submits to the exclusive jurisdiction

of the Federal and state courts in the Borough of Manhattan in The City of New York for the purpose of any suit, action or other proceeding

arising out of this Agreement or the transactions contemplated by this Agreement, the Registration Statement and any Preliminary Prospectus

or the Prospectus, (b) agrees that all claims in respect of any such suit, action or proceeding may be heard and determined by any such

court, (c) waives to the fullest extent permitted by applicable law, any immunity from the jurisdiction of any such court or from any

legal process, (d) agrees not to commence any such suit, action or proceeding other than in such courts, and (e) waives, to the fullest

extent permitted by applicable law, any claim that any such suit, action or proceeding is brought in an inconvenient forum. THE COMPANY

AND THE UNDERWRITER HEREBY WAIVE ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER BASED UPON CONTRACT, TORT OR OTHERWISE) IN

ANY WAY ARISING OUT OF OR RELATING TO THIS AGREEMENT. THE COMPANY AND THE UNDERWRITER HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH LEGAL

PROCEEDING BROUGHT IN ANY SUCH COURT SHALL BE CONCLUSIVE AND BINDING UPON THE COMPANY OR THE UNDERWRITER, AS APPLICABLE, AND MAY BE ENFORCED

IN ANY OTHER COURTS IN THE JURISDICTION OF WHICH THE COMPANY OR THE UNDERWRITER, AS APPLICABLE, IS OR MAY BE SUBJECT, BY SUIT UPON SUCH

JUDGMENT.

18.

UNDERWRITER’S INFORMATION. The parties hereto acknowledge and agree that, for all purposes of this Agreement, the Underwriter’s

Information consists solely of the statements concerning the Underwriter contained in the following paragraphs under the heading “Underwriting”

in the Prospectus: (i) the third paragraph under “- Discounts”; (ii) the paragraph under “-Discretionary Accounts”;

(iii) the paragraphs under “-Stabilization”; (iv) the paragraph under “-Passive Market Making”; and (v) the paragraph

under “-Electronic Offer, Sale and Distribution of Securities.”

19.

PARTIAL UNENFORCEABILITY. The invalidity or unenforceability of any section, paragraph, clause or provision of this Agreement shall

not affect the validity or enforceability of any other section, paragraph, clause or provision hereof. If any section, paragraph, clause

or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor

changes (and only such minor changes) as are necessary to make it valid and enforceable.

20.

GENERAL. This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written or oral

and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. In this Agreement,

the masculine, feminine and neuter genders and the singular and the plural include one another. The section headings in this Agreement

are for the convenience of the parties only and will not affect the construction or interpretation of this Agreement. This Agreement may

be amended or modified, and the observance of any term of this Agreement may be waived, only by a writing signed by the Company and the

Underwriter.

21.

COUNTERPARTS. This Agreement may be signed in any number of counterparts, each of which shall be an original, including by facsimile

or other electronic transmission, with the same effect as if the signatures thereto and hereto were upon the same instrument.

[Signature pages follow]

If the foregoing is in accordance

with your understanding please indicate your acceptance of this Agreement by signing in the space provided for that purpose below.

Very truly yours,

ANNOVIS BIO, INC.

By:

/s/ Maria Maccecchini

Name: Maria Maccecchini

Title: Chief Executive Officer

Accepted as of the date first above written:

CANACCORD GENUITY LLC

By:

/s/ Jennifer Pardi

Name: Jennifer Pardi

Title: Managing Director

SCHEDULE A

Name

Number of

Shares to be

Purchased

Number of

Accompanying

Warrants to be

Purchased

Canaccord Genuity LLC

7,895,000

7,105,500

Total

7,895,000

7,105,500

SCHEDULE B

General Use Free Writing Prospectuses

None.

SCHEDULE C

Pricing Information

Securities

to be Sold:

7,895,000

shares of Common Stock

Accompanying Warrants to purchase

7,105,500 shares of Common Stock

Public

Offering Price:

$1.90

per share of Common Stock and Accompanying Warrant

Accompanying

Warrant Exercise Price:

$2.25

per Warrant Share

Underwriting

Discounts and Commissions:

6.5%

SCHEDULE D

Testing-the-Waters Communications

None.

SCHEDULE E

Lock-Up Parties

Maria L. Maccecchini, Ph.D.

Michael B. Hoffman

Reid S. McCarthy

Claudine E. Bruck, Ph.D.

Mark White

EXHIBIT I

Form of Lock-Up Agreement

Form of Lockup Agreement

May __ , 2026

Canaccord Genuity LLC

Penn 1, One Pennsylvania Plaza, Suite 2900

New York, NY 10119

Re:

Proposed Confidentially Marketed Public Offering by Annovis Bio, Inc.

Ladies and Gentlemen:

The undersigned, a securityholder

and/or officer and/or a director of Annovis Bio, Inc., a Delaware corporation (the “Company”), understands that Canaccord

Genuity LLC (“Canaccord”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”)

with the Company relating to the proposed confidentially marketed public offering (the “Offering”) of shares (the “Shares”)

of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and warrants exercisable for

shares of Common Stock (the “Warrants” and together with the Shares, the “Securities”). The undersigned

acknowledges that Canaccord is relying on the representations and agreements of the undersigned contained in this lock-up agreement in

conducting the Offering and, at a subsequent date, in entering into the Underwriting Agreement and other underwriting arrangements with

the Company with respect to the Offering.

In recognition of the benefit

that the Offering will confer upon the undersigned as a securityholder and/or officer and/or a director of the Company, and for other

good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees that, during the

period beginning on the date hereof and ending on the date that is 90 days from the date of the Underwriting Agreement (the “Lock-Up

Period”), the undersigned will not (and will cause any immediate family member not to), without the prior written consent of

Canaccord, which may withhold its consent in its sole discretion, directly or indirectly, (i) sell, offer to sell, contract to sell or

lend, effect any short sale or establish or increase a Put Equivalent Position (as defined in Rule 16a-1(h) under the Securities Exchange

Act of 1934, as amended (the “Exchange Act”)) or liquidate or decrease any Call Equivalent Position (as defined in

Rule 16a-1(b) under the Exchange Act), pledge, hypothecate or grant any security interest in, or in any other way transfer or dispose

of, any Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock, in each case whether now owned

or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively,

the “Lock-Up Securities”), (ii) make any demand for, or exercise any right with respect to the registration of any

of the Lock-Up Securities, or the filing of any registration statement, prospectus or prospectus supplement (or an amendment or supplement

thereto) in connection therewith, under the Securities Act of 1933, as amended (the “Securities Act”), (iii) enter

into any swap, hedge or any other agreement or any transaction that transfers, in whole or in part, the economic consequence of ownership

of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, in cash

or otherwise, or (iv) publicly announce the intention to do any of the foregoing.

Notwithstanding

the foregoing, and subject to the conditions below, the undersigned may transfer the Lock-Up Securities pursuant to clauses (i) through

(vi) below without the prior written consent of Canaccord, provided that (1) in the case of clauses (i) through (v), prior to any

such transfer, Canaccord receives a signed lock-up agreement, substantially in the form of this lock-up agreement, for the balance of

the Lock-Up Period from each donee, trustee, distributee or transferee, as the case may be, (2) in the case of clauses (i) through (v),

any such transfer shall not involve a disposition for value, (3) any required public filings or report under Section 16 of the Exchange

Act during the Lock-Up Period shall clearly indicate in the footnotes thereto that the such transfer is being made pursuant to the circumstances

described below, and (4) the undersigned does not otherwise voluntarily effect any public filing or report regarding such transfers:

(i)             as

a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for bona

fide estate planning purposes; or

(ii)            to

any trust for the direct or indirect benefit of the undersigned or the immediate family (defined below) of the undersigned, or if

the undersigned is a trust, to a trustor, trustee or beneficiary of the trust or to the estate of a trustor, trustee, or beneficiary of

such trust; or

(iii)           to

any permitted transferee (defined below); or

(iv)           by

operation of law, such as pursuant to a qualified domestic order or in connection with a settlement related to the distribution of assets

in connection with the dissolution of marriage or civil union; or

(v)            by

will or intestate succession to the legal representative, heir, beneficiary or immediate family of the undersigned upon the death of the

undersigned; or

(vi)           pursuant to a bona

fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Common Stock that has been

approved by the Company’s board of directors, which results in any person or group of persons becoming the beneficial owners (as

defined in Rules 13d-3 and 13d-5 of the Exchange Act) of more than 50% of the outstanding voting securities of the Company (or the surviving

entity); provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed, the

Common Stock shall remain subject to the provisions of this lock-up agreement.

The undersigned further agrees

that the foregoing provisions shall be equally applicable to any Securities the undersigned may purchase or otherwise receive in the Offering.

Furthermore, notwithstanding

the restrictions imposed by this lock-up agreement, the undersigned may, without the prior written consent of Canaccord: (a) exercise

an option to purchase shares of Common Stock granted under any stock incentive plan of the Company, which plan is described in the prospectus

supplement related to the Offering, provided that the underlying shares of Common Stock shall continue to be subject to the restrictions

on transfer set forth in this lock-up agreement and if the undersigned is required to file a report under Section 16 of the Exchange Act

reporting a reduction in beneficial ownership of shares of Common Stock during the Lock-Up Period, the undersigned shall clearly indicate

in the footnotes thereto the nature and conditions of such exercise or transfer and no other filing or public announcement shall be made

voluntarily during the Lock-Up Period in connection with such exercise or transfer; (b) establish a trading plan pursuant to Rule 10b5-1

under the Exchange Act for the transfer of shares of Common Stock, provided that, such plan does not provide for any transfers

of Common Stock during the Lock-Up Period; (c) transfer or dispose of shares of Common Stock purchased in the Offering from the underwriters

or on the open market following the Offering, provided that no filing under the Exchange Act reporting a reduction in beneficial

ownership of shares of Common Stock shall be voluntarily made during the Lock-Up Period; or (d) sell Lock-Up Securities for tax withholding

purposes in connection with the vesting of equity awards that are subject to a taxable event upon vesting of the Company’s securities,

it being understood that all shares of Common Stock received upon such vesting or transfer will remain subject to the restrictions of

this lock-up agreement during the Lock-Up Period, and provided that if the undersigned is required to file a report under the Exchange

Act reporting a reduction in beneficial ownership of the undersigned’s Common Stock during the Lock-Up Period related to such disposition,

the undersigned shall include a statement in such report to the effect that the filing relates to the satisfaction of tax withholding

obligations of the undersigned in connection with such vesting event and no other filing or public announcement shall be made voluntarily

during the Lock-Up Period in connection with such vesting or transfer.

The undersigned also agrees

and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of

the Lock-Up Securities except in compliance with the foregoing restrictions.

With respect to the Offering

only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale of any shares

of Common Stock and/or any options or warrants or other rights to acquire Common Stock or any securities exchangeable or exercisable for

or convertible into Common Stock, or to acquire other securities or rights ultimately exchangeable or exercisable for or convertible into

Common Stock, owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering.

The undersigned confirms that

the undersigned has not, and has no knowledge that any immediate family member has, directly or indirectly, taken any action designed

to or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company

to facilitate the sale of the Securities. The undersigned will not, and will cause any immediate family member not to take, directly or

indirectly, any such action.

As used herein, “permitted

transferee” shall mean (a) the members of the undersigned’s immediate family (for purposes of this lock-up agreement, “immediate

family” shall mean the spouse, domestic partner, lineal descendant (including adopted and step-children) and his or her spouse,

father, mother, the siblings of such person and his or her spouse, or any other person with whom the undersigned has a relationship by

blood, marriage or adoption not more remote than first cousin), (b) if the undersigned is a corporation, limited liability company, partnership

or other entity, its partners, shareholders, members of, or owners of similar equity interests in the undersigned by way of distribution

upon the liquidation and dissolution of the undersigned or (c) any affiliate of the undersigned.

The undersigned represents

and warrants that the undersigned has full power, capacity and authority to enter into this lock-up agreement. This lock-up agreement

is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns of the undersigned.

This lock-up agreement shall

be governed by and construed in accordance with the laws of the State of New York.

Whether or not the Offering

actually occurs depends on a number of factors, including market conditions. Any Offering will only be made pursuant to an Underwriting

Agreement, the terms of which are subject to negotiation between the Company and Canaccord.

This lock-up agreement shall

automatically terminate, and the undersigned shall be released from its obligations hereunder, upon the earliest to occur, if any, of

(i) the Company advising Canaccord in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed

with the Offering, (ii) the executed Underwriting Agreement being terminated prior to the closing of the Offering (other than the provisions

thereof that survive termination), and (iii) May 29, 2026, in the event that the Underwriting Agreement has not been executed by such

date.

[Signature Page Follows]

Very truly yours,

Name of Securityholder/Director/Officer

(Print exact name)

By:

Signature

If not signing in an individual capacity:

Name of Authorized Signatory (Print)

Title of Authorized Signatory (Print)

(indicate capacity of person signing

if signing as custodian, trustee or on behalf of an entity)

ANNEX A

Form of Accompanying Warrant

WARRANT TO PURCHASE COMMON STOCK

ANNOVIS BIO, INC.

Warrant Shares: [     ]

Issue Date: May 21, 2026

THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”)

certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the

limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (the “Initial Exercise

Date”) and on or prior to 5:00 p.m. (New York City time) on that date that is six years from the Issue Date (the “Termination

Date”) but not thereafter, to subscribe for and purchase from Annovis Bio, Inc., a Delaware corporation (the “Company”),

up to [     ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of the

Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of

Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Section 1. Definitions. Capitalized terms

used and not otherwise defined herein shall have the meanings set forth in that certain Underwriting Agreement (the “Underwriting

Agreement”), dated May 20, 2026, by and between the Company and Canaccord Genuity LLC.

Section 2. Exercise.

(a)            Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time

or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed copy

submitted by email (or email attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”).